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In modern molecular genetic diagnostics a trend towards very small amounts of DNA 
down to the analysis of single cells can be observed in recent years. Therefore, 
techniques for precise isolation and transfer of specific sample material are required 
prior to analysis.  
In this work sample isolation was achieved using laser microdissection in combination 
with a low-pressure single particle adsorbing transfer system. Isolated samples were 
transferred horizontally to a planar chemically structured polymerase chain reaction 
(PCR) glass slide instead of into reaction tubes as is the case in most other 
microdissection techniques. On this glass slide, a low-volume PCR in a total reaction 
volume of 1 µl is performed. Reduction of the reaction volume has the potential to 
dramatically increase the efficiency and sensitivity of PCR compared to PCR in larger 
reaction volumes of up to 50 µl. It is therefore applicable to analyses at the single cell 
level. 
 
In the first part of this work, three colon polyps of two patients at risk for colorectal 
cancer (CRC) were characterized simultaneously regarding mutations of the two proto-
oncogenes BRAF and KRAS and microsatellite instability (MSI) status. Major aspects in 
CRC development are microsatellite instability, CpG island methylator phenotype and 
mutations in certain genes. The genes BRAF and KRAS are components of the MAPK 
ERK signalling pathway and gain-of-function mutations of either of them leads to the 
activation of the pathway and therefore to cell proliferation. 
Low-volume multiplex PCR directly from formalin-fixed paraffin-embedded polyp tissue 
sections (hyperplastic polyp, sessile serrated and tubular adenoma) was performed. It 
was demonstrated that hotspot mutations of BRAF and KRAS occurred simultaneously 
in the same sample isolated from one polyp of a patient. Furthermore, mutations in both 
genes, besides the hotspots, were detected very often in the same samples. In contrast, 
it was shown recently that mutations at the hotspots of BRAF (mutation V600E) and 
KRAS (codons 12, 13, 59, 61 and 63) are mutually exclusive in precursor lesions of 
sporadic microsatellite stable and MSI CRC. Compared to the CRC classification 
suggested by Jass, the results obtained in this work indicate an association with the 
serrated pathway model comprising mutations in BRAF and KRAS and MSI or 
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microsatellite stability. It was shown that characterization of such colon polyps is 
important for a better molecular understanding of colorectal cancer development.  
 
In the second part of this work a genetic test system for the specific detection of 
mutations in the adenomatous polyposis coli (APC) gene was established that is 
applicable to polar body diagnosis. Familial adenomatous polyposis of the colon is an 
autosomal dominant inherited disorder caused by mutations in the tumor suppressor 
gene APC. A characteristic of this severe disease is the development of hundreds to 
thousands of polyps in the colon starting in the first decade of age which untreated 
evolve into malignant colorectal carcinomas. In preimplantation genetic diagnosis 
(PGD), mutation analysis has to be performed on only few or even single cells e. g. 
blastomeres, blastocyst cells and polar bodies. Mutation analysis must therefore be 
carefully validated and optimized as regards amplification efficiency and the evaluation 
of allelic drop out rates before application to PGD.  
A multiplex nested PCR protocol in 1 µl reaction volume, followed by sequencing and 
fragment length analysis was applied in order to detect mutations in the APC gene. High 
amplification efficiency and low allelic drop out rates for polymorphic microsatellite 
markers and mutation-specific amplification products of various mutations in the APC 
gene were obtained from fixed single cells. This novel approach enables a reliable 
validation of genetic testing using diploid single lymphocytes, and will open a wide 
range of single cell diagnostics. Moreover, this fast and reliable technique for mutation 
analysis combining laser microdissection, horizontal transfer, low-volume PCR and 






In der modernen molekulargenetischen Diagnostik gibt es in den letzten Jahren einen 
Trend zur Untersuchung äußerst geringer DNA-Mengen bis hin zur Analyse von 
Einzelzellen. Daher sind Methoden zur präzisen Isolierung und dem Transfer von 
spezifischem Probenmaterial vor Beginn der Untersuchung erforderlich.  
In dieser Arbeit wurde die Probengewinnung durch Laser-Mikrodissektion in 
Kombination mit einem Unterdruck-Einzelpartikel-Transfersystem erzielt. Die isolierten 
Proben wurden durch horizontalen Transfer auf einen flachen, chemisch behandelten 
Polymerase-Kettenreaktions (PCR)-Glasobjektträger überführt anstatt, wie bei der 
Mehrzahl der Mikrodissektionsmethoden, in Reaktionsgefäße. Auf diesem Objektträger 
wurde eine sogenannte „low-volume“ (LV)-PCR in einem Gesamtreaktionsvolumen von 
1 µl durchgeführt. Die Reduzierung des Reaktionsvolumens ermöglicht eine erhebliche 
Steigerung der PCR-Effizienz und -Empfindlichkeit gegenüber größeren Reaktions-
volumina von bis zu 50 µl. Aus diesem Grund ist diese Methode auch auf Einzelzellen 
anwendbar. 
 
Im ersten Teil dieser Arbeit wurden drei Darmpolypen zweier Krebsrisiko-Patienten 
gleichzeitig bezüglich des Mikrosatellitenstatus’ sowie auftretender Mutationen in den 
Proto-Onkogenen BRAF und KRAS untersucht. Hauptaspekte bei der 
Darmkrebsentstehung sind Mikrosatelliteninstabilität (MSI), Methylierung von CpG 
Inseln von Genpromotoren und Mutationen in bestimmten Genen. Die Gene BRAF und 
KRAS sind Komponenten des MAPK ERK Signalwegs. Funktionsgewinn-Mutationen in 
einem der beiden Gene führt zur Signalwegsaktivierung und infolgedessen zu 
vermehrtem Zellwachstum.  
Eine LV-multiplex-PCR wurde direkt ohne Zwischenschritte mit fixiertem Polypengewe-
be (hyperplastischer Polyp, sessil serratiertes und tubuläres Adenom) durchgeführt. Es 
wurde gezeigt, dass Mutationen in häufig mutierten Bereichen von BRAF und KRAS 
gleichzeitig in derselben Probe eines Polypen eines Patienten vorkommen. Darüber 
hinaus wurden andere Mutationen in beiden Genen häufig gleichzeitig in denselben 
Proben nachgewiesen. Im Gegensatz dazu haben mehrere Studien nachgewiesen, 
dass sich sogenannte „Hotspot“-Mutationen von BRAF (V600E) und KRAS (Codons 12, 
13, 59, 61 und 63) in Vorläuferläsionen von sporadischem Darmkrebs (mikrosatelliten-
stabil oder -instabil) gegenseitig ausschließen. Verglichen mit der vorgeschlagenen 
Abstract 7 
 
Einteilung nach Jass weisen die Ergebnisse dieser Arbeit eine gewisse 
Übereinstimmung mit dem „Serratierten Karzinogeneseweg“ auf. Dieser beinhaltet 
Mutationen in den Genen BRAF und KRAS sowie Mikrosatelliteninstabilität oder  
-stabilität. Es konnte gezeigt werden, dass die Charakterisierung solcher Darmpolypen 
für ein besseres molekulares Verständnis der Darmkrebsentstehung wichtig ist. 
 
Im zweiten Teil der Arbeit wurde ein genetisches Testsystem zum spezifischen 
Nachweis von Mutationen im APC Gen etabliert, das auch für die Polkörperdiagnose 
anwendbar ist. Familiäre adenomatöse Polyposis ist eine autosomal dominant vererbte 
Krankheit, die durch Mutationen im Tumorsuppressorgen APC verursacht wird. Ein 
Merkmal dieser schweren Krankheit ist die Entstehung hunderter bis tausender 
Darmpolypen beginnend im ersten Lebensjahrzehnt, die unbehandelt ein erhöhtes 
Krebsrisiko bergen. In der Präimplantationsdiagnostik stehen wenige oder sogar nur 
eine einzige Zelle für eine Untersuchung zur Verfügung, z. B. Blastomeren, 
Blastocysten oder Polkörper. Daher muss die Mutationsanalyse bezüglich 
Amplifikationseffizienz und Allel-Ausfallraten sorgfältig überprüft und optimiert werden, 
bevor sie in der Präimplantationsdiagnostik angewendet werden kann.  
Zum Nachweis der APC Mutationen wurden eine LV-multiplex-PCR und anschließende 
Sequenz- sowie Fragmentlängenanalysen durchgeführt. Sowohl bei den polymorphen 
Mikrosatellitenmarkern als auch bei den spezifischen PCR-Produkten verschiedener 
APC Mutationen wurden eine hohe Amplifikationseffizienz und geringe Allel-Ausfallraten 
mit fixierten Einzelzellen erzielt. Dieser neuartige Ansatz ermöglicht die zuverlässige 
Etablierung eines genetischen Testsystems für diploide Lymphozytenzellen. Darüber 
hinaus erlaubt diese schnelle und zuverlässige Art der Mutationsanalyse eine 
Anpassung an viele verschiedene Fragestellungen, sowohl im Bereich der 
molekularbiologischen als auch der Einzelzell-Forschung. 




2.1 Molecular genetic diagnostics 
 
Exiting advances in developing more sensitive and faster methods for analyzing 
increasingly less biological sample material have been made in recent years. A trend 
towards very small amounts of DNA down to the analysis of single cells can be 
observed (Hagen-Mann et al. 2005). Existing cytogenetic analysis methods like 
fluorescence in situ hybridization (FISH) or comparative genome hybridization (CGH) 
have been modified and optimized to be applicable for single cells. For example, the 
combination of such high-throughput and high-resolution methods with whole genome 
amplification (WGA) techniques display a great advantage in analyzing small amounts 
of starting material (Speicher and Carter 2005, Fiegler et al. 2007). In this context, chip 
and array technologies play an increasingly important role in molecular genetic 
diagnostics (Reyes et al. 2002, Auroux et al. 2002, Matsubara et al. 2005, Dittrich et al. 
2006). A sensitive and reliable analysis of the smallest amounts of sample material 
constitutes the basis not only of forensic case work (Yeung et al. 2006) but also of 
preimplantation genetic diagnosis (PGD) and tumour tissue analysis. The major aspect 
of PGD is the analysis of few or single cells. A rising number of genetic and inherited 
disorders is now applicable to PGD (Findlay 2000, Kuliev et al. 2007, Spits and Sermon 
2009). Analysis of small tissue samples and few or even single cells demonstrates a 
fundamental factor for heterogeneous tumour tissue examination (Hoque et al. 2003, 
Klein 2005). 
In all these cases sample material must be isolated or gained in an appropriate manner 
prior to analysis. 
 
 
2.2 Laser microdissection and SPATS 
 
The retrieval and isolation of specific sample material and single cells and their precise 
positioning for further analysis therefore constitutes a basic aspect of modern molecular 
and genetic diagnostics. Up to now, different methods for the isolation of single cells or 
particles have been in routine laboratory use, e.g. extraction via fluorescence-activated 
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cell sorting (FACS) (Herzenberg et al. 2002, Nunes et al. 2003), hand or glass needle 
microdissection (Weimer et al. 2001, Croner et al. 2004, Bazan et al. 2005) and a broad 
variation of laser-based microdissection techniques such as laser capture (Schütze and 
Lahr 1998, Simone et al. 1998, Curran et al. 2000), laser pressure catapulting 
(Thalhammer et al. 2003, Bazan et al. 2005, Kirschner and Plaschke-Schluetter 2007) 
or isolation via gravity effects (Di Martino et al. 2004).  
For isolation of fresh single cells floating in a medium, FACS is the method of choice 
used prior to analysis. However, the cells either need to be identified using 
fluorescence-labelled antibodies which bind to specific surface markers of the cell 
membrane or are sorted by size and shape (Bonner et al. 1972). This method is thus 
disadvantageous when analyzing solid tissue samples as, for example, tumour biopsies. 
Instead, microdissection techniques enable the precise manipulation and isolation of 
genetic material within a range of several micrometers, from fragments of histological 
tissue sections down to single cells or single chromosomes (Lechner et al. 2003, 
Thalhammer et al. 2004). 
Two main types of laser-based microdissection methods can be distinguished: laser 
capture and laser cutting microdissection. In laser capture microdissection an infrared 
laser with diameters ranging from 7 to 30 µm is used. The laser melts parts of a 
thermoplastic membrane, mounted on a plastic cap which is located directly above the 
cells or sample material of interest. These cells then attach or adhere to the membrane 
and can be picked up from the tissue section once the membrane has cooled down. 
Using this method, only relatively large samples can be isolated whereas laser cutting 
methods allow precise isolation of small numbers or even single cells from tissue 
sections. This is achieved by using a UV laser with diameters less than 1 µm where the 
sample of interest is surrounded with the laser beam and cut out of the section (for 
review, see Murray 2007). Independent of which type of laser microdissection is used, 
the isolated samples are transferred into reaction tubes. In most cases cells are 
transferred in the cap of the tube containing a droplet of fluid, e. g. a lysis buffer, in 
which the sample was collected and further processed. Although the isolation process is 
performed under optical control, there may be certain difficulties in controlling the 
presence of the sample in the cap due to the relatively large size and the opaqueness of 
the cap with the droplet containing a small sample, e. g. a single cell (Schütze and Lahr 
1998).  
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For this reason the isolation of sample material in this work was achieved using laser 
microdissection in combination with the recently developed low-pressure single particle 
adsorbing transfer system (SPATS). Samples were isolated using conventional laser 
cutting microdissection and were then adsorbed to a sample collection grid via low-
pressure instead of transferring it into a tube cap via laser pressure catapulting or 
gravity effects. This approach allows the transfer of the isolated material to a planar 
chemically structured glass slide with micrometer precision (Woide et al. 2009). The 
deposition of a single particle specifically to a reaction centre on a planar chemically-
structured polymerase chain reaction (PCR) device is facilitated by microscopic control 
of the entire process including sample transfer and release. After samples are isolated 
and transferred, further processing and analysis can be performed starting with PCR. 
 
 
2.3 Polymerase chain reaction 
 
Low-volume PCR 
In general, PCR is performed in a total reaction volume of 10 to 50 µl using at least 1 up 
to 25 ng/µl of template DNA per reaction (Hunt 2008). This is an effective approach in 
normal routine laboratory analysis where sufficient amounts of genomic DNA are 
available. However, when only a limited amount of template DNA is available, e. g. from 
small biopsy samples or in PGD, there is a need for analyzing only a few or even single 
cells. As it was shown recently, reduction of the reaction volume has the potential to 
dramatically increase the efficiency and sensitivity of PCR and is therefore applicable to 
analyses at the single cell level (Schmidt et al. 2005, Proff et al. 2006, Lutz-Bonengel et 
al. 2007). In this context, miniaturization of PCR devices displays a great advantage and 
replaces PCR performed in a conventional reaction tube. Low-volume PCRs can be 
performed on so-called PCR chips which vary in size, architecture, material and PCR 
procedure. Differentiation can be made concerning single or multi-chamber chips, 
planar PCR devices with chemically modified surface structures or multi-channel chips. 
In stationary PCR devices, the PCR mixture does not move during PCR while it flows or 
is pumped through micro channels in the continuous-flow PCR devices. Altogether, a 
markedly reduced thermal mass of the entire PCR system effects rapid heating and 
cooling rates and therefore enables PCR reactions in less time with increased efficiency 
(for review, see Zhang and Xing 2007). 
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On the planar PCR glass slide used for this work, a 1-µl droplet of PCR mixture forms 
its own ‘virtual’ reaction chamber, held together by surface tension due to the 




The principle of nested PCR is the amplification of a specific sequence using two 
different pairs of primers in two sequent PCR reactions. The first or outer primer pair 
amplifies a specific locus as in conventional PCR reactions. The second or inner 
(nested) primer pair binds within a position of the first amplification product and 
generates a secondary PCR product which is shorter than the first one. Nested PCR 
increases the specificity of the PCR reaction as the probability of amplifying an 
additional homologous sequence is reduced. A higher yield of specific PCR product 
serves as template in the secondary amplification and replaces unspecific DNA 
fragments (Hashimoto et al. 1995). Combination of a low-volume PCR with nested 
primers additionally raises the yield of specific PCR product compared to a single PCR 
reaction and allows several subsequent analyses using low amounts of DNA or single 
cells as template. 
 
 
2.4 Colorectal cancer 
 
In Germany, colorectal cancer (CRC) is the second most frequent tumour disease and 
cause of death amongst all cancer syndromes in men and women. Every year, CRC is 
diagnosed in about 37,000 men and 36,000 women for the first time. Despite this high 
incidence, a continuous decline of mortality rates in the last decades due to improved 
diagnosis and therapy can be observed. The mean age of disease diagnosis is 69 years 
for men and 75 years for women (source: Robert Koch-Institut). For these reasons, 
understanding and researching this severe disorder constitutes the basis for further 
improvement in diagnosis and therapy and should also result in better prevention. 
Colorectal cancer is a very heterogeneous disorder and the term includes all cases of 
cancer in the colon, rectum and anus.  
The majority of CRC cases are sporadic, 10% constitute inherited forms of CRC and 
about 20% are familial polygenic (St. John et al. 1993, Salovaara et al. 2000, Peto and 
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Houlston 2001, Olsson and Lindblom 2003, Aaltonen et al. 2007). Hereditary non-
polyposis colorectal cancer (HNPCC) syndromes constitute a major part of inherited 
cancer with about 5-10% and about 2% of all CRC account for familial adenomatous 
polyposis (FAP) (Lynch 1999, Turnbull and Hodgson 2005). Inherited cancer is mainly 
differentiated by the number of polyps or adenomas found in the colon. Other inherited 
cancer syndromes like Peutz-Jeghers syndrome, familial juvenile polyposis or Cowden 
syndrome are very rare (Turnbull and Hodgson 2005, Friedl and Propping 2007). 
 
In HNPCC (OMIM 120435, 120436) polyps occur in the colon with a proximal colonic 
predominance. Usually, a significantly less number of polyps is observed compared to 
FAP, hence the name non-polyposis syndrome. Despite a relatively small number of 
polyps, the risk of malignant transformation is very high for an individual polyp. 
Carcinogenesis is accelerated in HNPCC with development of adenomas to carcinomas 
occurring in 2-3 years compared to 8-10 years. In the majority of cases autosomal 
dominant inheritance is observed in HNPCC but in cases with de novo germ line 
mutations in one person family anamnesis cannot be taken into account for diagnosis 
(Lynch 1999). The genetic basis for HNPCC are germ line mutations in one of the DNA 
mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2. Mutations in MLH1 
(chr. 3p21.3) and MSH2 (chr. 2p16) account for the majority of cases (Wang et al. 2003, 
v. d. Klift et al. 2005). HNPCC is defined as familial CRC including cases with mismatch 
repair gene mutation and microsatellite instability as well as cases with microsatellite 
stable tumours designated as ‘familial colorectal cancer type X’ (Lindor et al. 2005). The 
DNA mismatch repair system is responsible for exact replication of DNA in the cell. 
Patients with a germ line mutation on one allele of an MMR gene have an increased risk 
of developing cancer, and tumourigenesis is induced when an additional alteration 
occurs at the second allele. Loss-of-function of the system, e. g. due to mutations in 
both alleles of a repair gene leads to accumulation of errors and mutations in the 
genome. Specific repeating motifs, the so-called microsatellite regions are prone to 
such replication errors. Defect in the MMR system results in shortened or elongated 
microsatellite sequences and this effect, called microsatellite instability (MSI; Fig. 1) is a 
hallmark of tumours in HNPCC patients (Gebert and v. Knebel Doeberitz 1999, Lynch 
1999). For detecting MSI in colorectal cancer specific criteria were defined and a set of 
specific microsatellite markers including BAT25, BAT26 and BAT40 which are used 
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here, was determined in a National Cancer Institute workshop on microsatellite 
instability in 1998 (Boland et al. 1998). 
 
 
Fig. 1: Microsatellite instability (MSI) is indicated by changes in the 
resulting regular peak pattern of the wild type (wt) BAT26 marker. 
 
In addition to microsatellite marker analysis on the genomic level for detecting MMR 
deficiency, the immunohistochemical staining of proteins in cells of tumour tissue 
enables analysis of mismatch repair gene expression. Presence or absence of the 
analogous protein can be detected using labelled antibodies binding to the protein in the 
cells. However, the sensitivity of immunohistochemical staining analysis is reduced 
compared to MSI analysis due to false positive signals when a non-functional protein is 
present in the cell (Holinski-Feder and Morak 2010). 
 
Familial adenomatous polyposis of the colon (OMIM 175100) is an autosomal dominant 
disorder or, in rare cases, recessively inherited by mutations in MUTYH (Groden et al. 
1991, Sampson et al. 2005). FAP is characterized by hundreds to thousands of 
adenomas occurring in the colon starting in the second decade of life and is therefore 
classified as a polyposis syndrome. In the majority of cases, mutations of the 
adenomatous polyposis coli (APC) gene (chr. 5q22.2) are responsible for developing 
FAP (Nakamura 1995). The protein product of the APC gene is an important component 
of the wnt signaling pathway which is responsible, among other factors, for cell 
proliferation (Clevers 2004). The main function of APC is the regulation of the 
intracellular ß-catenin level. In non-proliferating cells APC in combination with other 
proteins in their active conformation phosphorylate ß-catenin; the resulting degradation 
leads to a low ß-catenin level in the cell. Disruption of this pathway due to mutations in 
the APC gene inhibits phosphorylation of ß-catenin and results in a high intracellular ß-
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catenin concentration. Free ß-catenin is translocated into the nucleus and activates 
transcription factors responsible for cell proliferation. In normal colon mucosa the 
activation of the wnt signaling pathway leads to increased proliferation of cryptic stem 
cells. Cells evolved from these stem cells at the bottom of a crypt replace older and 
apoptotic cells at the top of the crypt. Thus, the colon mucosa is permanently renewed. 
Most of the mutations in the APC gene are nonsense point mutations or frame-shifts 
due to insertions or deletions which result in truncated non-functional proteins 
(Nakamura 1995, Ballhausen 2000). In rare cases FAP can be recessively inherited by 
mutations in MUTYH involved in base excision repair of 8-oxo-Guanine. 
For several decades the adenoma – carcinoma sequence was thought to be the only 
carcinogenesis pathway through which cancer could evolve. This so-called Vogelstein 
pathway described the accumulation of multiple mutations in several genes, mostly 
beginning with an initial APC mutation. Over the years, point mutations in the KRAS and 
TP53 genes were shown to contribute to carcinogenesis and development of colorectal 
cancer. A chromosomal instability with an aberrant number of chromosomes as well as 
chromosomal translocations could then also be detected (Vogelstein et al. 1988, Fearon 
and Vogelstein 1990, Mitelman et al. 2007). This pathway was supposed to provide the 
explanation for CRC evolution not only in FAP, which is initiated by APC mutations, but 
also in sporadic cases (Fearon and Vogelstein 1990).  
Despite two mutually exclusive types of genetic instability (microsatellite and 
chromosomal instability), the existence of only one main pathway with certain variations 
for sporadic and inherited CRC development based on the adenoma – carcinoma 
sequence was supposed (Kinzler and Vogelstein 1996). The occurrence of Lynch 
syndrome patients with MSI-high (MSI-H) and mutations in APC, KRAS and TP53 
seems to confirm this fact. However, MSI-H consistent with mutations in MMR genes 
(characteristics of Lynch syndrome) could rarely be observed in sporadic adenomas. 
Additionally, mutations in APC, KRAS or the ß-catenin (Clevers 2004) gene which are 
associated with initialization and early progress in the Vogelstein pathway could rarely 
or not at all be found in sporadic MSI-H CRC. In contrast, mutations in the BRAF gene 
and methylation of the MLH1 promoter are typical genetic alterations in sporadic CRC 
but not in Lynch syndrome. For these reasons there was a need for defining another 
pathway which could explain the discrepancies between sporadic and inherited cancer 
(for review, see Jass 2007). 
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Microsatellite instability is caused mainly by a non-functional or inactive MLH1 gene, e. 
g. due to germ line mutations occurring in Lynch syndrome and somatic loss of 
heterozygosity. In sporadic CRC an MLH1 mutation is absent and another explanation 
for MSI is necessary: the CpG island methylator phenotype (CIMP; Toyota et al. 1999, 
Issa 2004). Methylation of cytosine appearing in GC-rich sequences (CpG islands) in 
the genome is an essential epigenetic mechanism necessary for gene expression 
regulation (Jones and Baylin 2002). Abnormal methylation of especially MLH1 as well 
as MGMT (O6-methylguanine-DNA methyltransferase) gene promoter in sporadic CRC 
leads to inactivation of these genes and thus to microsatellite instability. CIMP causing 
gene silencing due to increased promoter methylation is an important feature in 
carcinogenesis (Issa 2004). Methylation is not only limited to MLH1 and MGMT but can 
also occur in apoptosis-associated genes (for review, see Mäkinen 2007). Methylation 
of different genes results in different grades of microsatellite instability. The aberrant 
methylation pattern is often caused by mutations in either one of the proto-oncogenes 
BRAF (v-raf murine sarcoma viral oncogene homolog B1) or KRAS (v-Ki-ras2 Kirsten 
rat sarcoma viral oncogene homolog). The combination of CIMP, microsatellite 
instability and mutations in BRAF or KRAS are defining criteria for the serrated 
neoplasia pathway.  
On the basis of MSI and CIMP, multiple carcinogenesis pathways were classified in five 
subgroups, supported by the integration of histological, morphological and clinical 
characteristics of CRC (Jass 2007).  
 
1: CIMP-H, methylation of MLH1 resulting in MSI-H, associated with BRAF mutation 
2:  CIMP-H, partial methylation of MLH1 resulting in MSI-L or MSS, associated with 
BRAF mutation 
3:  CIMP-L, methylation of MGMT resulting in MSI-L or MSS, associated with KRAS 
mutation; chromosomal instability 
4:  CIMP-negative, no methylation and therefore MSS; chromosomal instability 
5:  CIMP-negative, inherited MMR deficiency resulting in MSI-H 
 
Microsatellite instability and CIMP are distinguished into high- (H) and low- (L) levels as 
well as microsatellite stability (MSS) or CIMP-negative (Boland et al. 1998, Ogino et al. 
2006). Serrated polyps are the precursor lesions of groups 1 and 2 consistent with the 
serrated pathway. Precursor lesions of the fourth (Vogelstein pathway) and the last 
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subtype (Lynch syndrome or HNPCC) are basically adenomas which evolve through the 
adenoma-carcinoma sequence. Colorectal cancer of subgroup 3 is assumed to develop 
from either type of polyp (for review, see Jass 2007). 
Generally, colon polyps are histologically classified as adenoma, serrated adenoma, 
sessile serrated adenoma (SSA), hyperplastic polyp (HP) and various subtypes or 
mixed forms of them (for reviews, see Young and Jass 2006, Mäkinen 2007). 
Classification is based on tissue and crypt structure, cell morphology and abnormal 
proliferating features of the crypt cells. One important characteristic of colon polyps, the 
serrated morphology can be differentiated into top-down or bottom-up morphology, 
which depends on the type of affected cells (Holinski-Feder and Morak 2010). Top-
down neoplasia develops when apoptosis of cells at the crypt top is decreased or 
delayed which results in a sawtooth-like infolding of the crypt tissue. Abnormal 
increased proliferation of the crypt stem cells leads to an elongated mitosis area at the 
bottom of the crypt which results in a similar crypt structure. Both the top-down and the 
bottom-up neoplasia cause serration of colon polyps. Therefore, classification of polyps 
exclusively according to their similar or mixed morphology has proven to be difficult. 
 
As shown above, microsatellite instability as well as mutations in the BRAF and KRAS 
genes play a major role in colorectal cancer development and classification. 
The two proto-oncogenes BRAF and KRAS both are components of the same 
intracellular signalling MAPK-ERK pathway. Extracellular signals are transduced via 
Kras and Braf to several other proteins which finally activate transcription factors in the 
nucleus. Regulation of cell proliferation, differentiation and apoptosis is performed via 
this pathway. KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
OMIM190070, chr. 12p12.1) a member of the ras superfamily is a small GDP/GTP 
binding protein attached to the inner cell membrane. Extracellular binding of a ligand 
triggers, through a series of adaptor proteins and exchange factors, the activation of 
Kras. Active Kras binds and actives the serine-threonine protein kinase Braf (V-raf 
murine sarcoma viral oncogene homolog B1; OMIM164757; chr. 7q34) which in turn 
activates several downstream protein kinases. Hyperactivation of this pathway leads to 
increased cell proliferation and displays an early event in carcinogenesis (Weinberg 
1982, Garnett and Marais 2004, Kranenburg 2005). Mutations in these two genes are 
responsible for hyperactivation of the pathway. The mutation c.1799 T>A, p.V600E in 
exon 15 of  the BRAF gene, an amino acid substitution from valine to glutamic acid, is a 
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well-characterized activating mutation (Davies et al. 2002, Kumar et al. 2003). Mutations 
in codons 12, 13, 59, 61 and 63 of the KRAS gene can lead to activation of the protein 
as well (Grimmond et al. 1992). Amino acid substitutions normally modify the protein 
structure. Depending on which amino acid is exchanged, the protein may not be able to 
change between its active and inactive conformation any longer or its ligand binding site 
becomes inaccessible. In the cases mentioned for Braf and Kras, the proteins stay 
locked in their active conformation which therefore leads to a hyperactivated pathway 
(Kranenburg 2005). 
 
Due to this significant role in carcinogenesis, the analysis of mutations in the BRAF and 
KRAS genes as well as microsatellite instability constitutes a major goal in cancer 
research. Combination of laser microdissection with the newly developed horizontal low-
pressure transfer system SPATS and low-volume multiplex PCR enables the 
simultaneous and sensitive analysis of smallest polyp tissue particles. In this way 
heterogeneous colon polyp tissue can be characterized or even mapped due to 
mutations in BRAF and KRAS and the microsatellite status down to small and almost 
homogeneous parts of a single crypt. This approach enables the exact analysis of the 
molecular nature and the development of a colon polyp which perhaps could promote 
advances in classification of CRC and the carcinogenesis pathways. 
 
 
2.5 Single cell analysis and preimplantation genetic diagnosis 
 
The ability to analyze individual single cells plays an increasingly important role in 
molecular genetic diagnostics. Recently, mutation analysis of inherited monogenic 
disorders was successfully established (Sermon 2002, Hehr et al. 2009, Spits and 
Sermon 2009, Vanneste et al. 2009). In preimplantation genetic diagnosis, mutation 
analysis must be performed on only a few or even single cells. 
For couples who wish to have children but are at high risk of passing a genetic disease 
on to their offspring, PGD offers the possibility to detect such diseases prior to 
implantation of the embryo. Generally, three types of cells are used for PGD: 
blastomeres, blastocyst cells and polar bodies. Blastomeres and blastocyst cells are 
biopsied from the developing embryo at day 3 or 5 postfertilization when it reaches the 
eight-cell or blastocyst stage, respectively (Sermon et al. 2004, Spits and Sermon 
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2009). In these cases, two or up to 10 diploid cells are available for analyzing the 
genetic status of the embryo (McArthur et al. 2005). In contrast, polar bodies develop 
during meiosis of the oocyte and allow the analysis of only the maternal genome. In 
polar body diagnosis, only one haploid single cell is available for analysis (Findlay 2000, 
Sermon et al. 2004). 
The low quantity of DNA on single cells leads to a number of complications in mutation 
analysis which are rarely found in routine diagnostics. Mutation analysis must therefore 
be carefully validated and optimized as regards amplification efficiency and the 
evaluation of allelic drop out (ADO) rates before application to PGD, especially polar 
body diagnosis. The main reason why polar body diagnosis is chosen as an example is 
the legal situation in Germany where manipulation of embryos is forbidden by law and 
polar bodies are the only option for PGD (Tomi et al. 2005, Hehr et al. 2007). In all 
cases time is a limiting factor in PGD and analysis has to be performed in less than 24 h 
(Tomi et al. 2005, Spits and Sermon 2009). 
The goal of the second part of this work is the establishment of a genetic test system for 
the specific detection of mutations in the APC gene (OMIM 611731) (Mayer et al. 2009). 
A fast and reliable technique for mutation analysis of single cells combining laser 









                                             
ADO    allelic drop out 
APC    adenomatous polyposis coli 
bp    base pairs 
BRAF    v-raf murine sarcoma viral oncogene homolog B1 
cDNA    complementary DNA 
CGH    comparative genomic hybridization 
CIMP    CpG island methylator phenotype 
CRC    colorectal cancer 
DNA    deoxyribonucleic acid    
F    forward 
FACS    fluorescence-activated cell sorting 
FAP    familial adenomatous polyposis  
FISH    fluorescence in situ hybridization 
H    high 
HE    hematoxylin and eosin 
HNPCC   hereditary non-polyposis colorectal cancer 
HP    hyperplastic polyp 
KRAS    v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
L    low 
LV    low-volume  
MAPK-ERK mitogen-activated protein kinase extracellular signal-
regulated kinase (signalling pathway) 
MDA    multiple displacement amplification 
MGMT   O6-methylguanine-DNA methyltransferase 
MLH1    mutL homolog 1 
MMR    mismatch repair 
mRNA   messenger ribonucleic acid 
MSH    mutS homolog 
MSI    microsatellite instability 
MSS    microsatellite stability 
mut    Mutation; mutated 
MUTYH   mutY homolog 
Abbreviations 20 
OGG1   8-oxoguanine DNA glycosylase 
PCR    polymerase chain reaction 
PEN    polyethylene-naphthalate 
PGD    preimplantation genetic diagnosis 
R    reverse 
rpm    rounds per minute 
SPATS   single particle adsorbing transfer system 
SSA    sessile serrated adenoma 
TD    touch down 
TP53    tumour protein p53 
UV    ultraviolet 
WGA    whole genome amplification 
wt    wild type 
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4.1.1 Colon polyps 
In total, three colon polyps of two patients were analyzed. Polyp 2320-08-IV of patient A 
was localized in the sigmoid colon. Extended mucosa with elongated crypts and a well 
matured crypt epithelium was observed. There was no evidence of a neoplastic polyp. It 
was classified as hyperplastic polyp with no malignant potential. Histological 
differentiation of the second polyp (4407-09) of patient A and classification as 
hyperplastic polyp or sessile serrated adenoma (SSA) was not possible. For the father 
of patient A, a hereditary non-polyposis colon carcinoma (HNPCC or Lynch syndrome) 
and additional hyperplastic colon polyps and serrated adenomas were diagnosed. He 
carries a non-functional allele in the MLH1 gene with an unknown pathomechanism 
which was assigned to MLH1 exon 8, c.655A by cDNA analysis. Patient A has inherited 
the functional copy of her father’s MLH1 gene.  
The analyzed polyp (13342-f1) of patient B was localized in the rectum. One part was 
classified histologically as sessile serrated adenoma, the other part as tubular 
adenoma. No evidence of a high-grade intraepithelial neoplasia in the tubular adenoma 
was observed. 
For both patients, genomic wild type DNA was analyzed as a reference. DNA was 
obtained from a blood sample of patient A and from paraffin-embedded normal mucosa 
tissue of patient B. This reference DNA was provided by the Medical Genetics Center, 
Munich. All histological characterizations were performed by the Laboratory for 
Pathology and Cytology of Dr. Funk, Dr. Dettmar and Prof. Dr. Sarbia, Munich, the 
Klinikum Garmisch-Partenkirchen or the Klinikum München Neuperlach. 
Patient consent for molecular analysis of their tissue samples was obtained. 
 
4.1.2 Familial adenomatous polyposis coli  
Three patients with familial adenomatous polyposis coli (FAP) heterozygous for 
mutations in exon 15 of the adenomatous polyposis coli (APC) gene (patient C: 
c.2612delG; patient D and E: c.3183-3187delACAAA) and cells of an unaffected male 
were used for the establishment of single cell polymerase chain reaction (PCR). The 
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deletions of all three patients are germ line mutations and are therefore detectable in 
lymphocyte cells isolated from blood samples. 
All three patients wished to have an unaffected child and underwent polar body analysis 
prior to pregnancy. Therefore, a genetic test system for single cell analysis applicable 
for polar body diagnosis was established. 
 
 
4.2 Preparations for laser microdissection 
 
4.2.1 Tissue preparation 
After surgical resection from the patients, the colon polyps were immediately formalin-
fixed and embedded in paraffin according to standard protocols (Lehmann and Kreipe 
2001, Bova et al. 2005). For laser microdissection, 6 µm thick tissue sections of the 
paraffined tissue blocks were prepared and applied to a 2 µm polyethylene-naphthalate 
(PEN) membrane mounted on a glass slide (Carl Zeiss MicroImaging GmbH, Munich, 
Germany). Tissue sections for laser microdissection were unstained but for histological 
classification some sections of each polyp, mounted on a normal glass slide, were 
hematoxylin and eosin (HE) stained (Bova et al. 2005). For microsatellite analysis, 
immunohistological staining relative to MLH1 gene expression was applied to some 
tissue sections of each polyp (Bova et al. 2005). Stained and unstained tissue sections 
were provided by the Laboratory for Pathology and Cytology of Dr. Funk, Dr. Dettmar 
and Prof. Dr. Sarbia. Histological classification of the colon polyps as well as the 
analysis of MLH1 staining was provided by the Klinikum Garmisch-Partenkirchen GmbH 
and the Laboratory for Pathology and Cytology. 
For removing the paraffin, PEN-slides with paraffin-embedded tissue sections were 
incubated for 30 minutes in xylene. Tissue slides were dehydrated in a decreasing 
ethanol series with incubation for 5 minutes in 100% ethanol, 2 minutes in 90% ethanol 
and 2 minutes in 70% ethanol. The slides were carefully removed from the solutions to 
prevent separation of the tissue sections from the PEN slides. Tissue section slides 
were completely dried at least 30 minutes at room temperature and about 30 minutes at 
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4.2.2 Single cell preparation 
Human lymphocytes were isolated from peripheral blood samples (patients C, D, E; 
Medical Genetic Center). Fixed lymphocytes were prepared according to the following 
protocol: About 5 to 10 droplets of anti-coagulated blood were incubated in 9 ml of 
chromosome medium B (Biochrom AG, Berlin, Germany) at 37°C for 71.5 hours. 
Thereafter 100 µl of colchicine (Biochrom AG, Berlin, Germany) were added and 
properly mixed with the cell suspension and incubated at 37°C for 30 minutes. The 
samples were centrifuged for 10 minutes with 1000 rpm (190 rcf; Rotina 35R, Hettich 
Zentrifugen, Tuttlingen, Germany) at room temperature and supernatant was discarded. 
The pellets were resuspended in 1 ml 75 mM KCl first and then filled up to 9 ml. The cell 
suspensions were then incubated at 37°C for 20 minu tes. For fixation of the cells, 1 ml 
of fixing solution (3:1 v/v methanol/glacial acetic acid) was added and mixed and the 
samples were incubated for 5 minutes at 4°C. The ce ll suspensions were centrifuged for 
10 minutes at 1000 rpm at room temperature and supernatant was discarded. The 
pellets were resuspended in fixing solution and incubated for 20 to 30 minutes at -20°C. 
Subsequently, the samples were washed in fixing solution until the cell suspensions 
were clear without contamination of red blood cells. Fixed cell suspensions were stored 
at -20°C. 
For laser microdissection fixed single lymphocytes were applied to a PEN membrane 
glass slide (Carl Zeiss MicroImaging GmbH, Munich, Germany). Fixed cell suspensions 
were washed once with fixing solution and supernatant was removed except for 1 ml in 
which the pellet was resuspended. Some droplets of this concentrated cell suspension 
were pipetted to the PEN slides and dried at room temperature. 
For cell nucleus staining, slides were incubated for 5 minutes in 5% (v/v) Giemsa 
solution (Merck KGaA, Darmstadt, Germany) diluted in phosphate buffered saline buffer 
(PBS Dulbecco, Biochrom AG, Berlin, Germany). After incubation the slides were 
washed with distilled water and completely dried at 37°C for about 30 minutes. For 
isolation of single cells slides were always unstained. 
 
 
4.3 Laser microdissection  
 
Laser microdissection was performed using an inverted optical microscope (Axio 
Observer.Z1, Zeiss, Oberkochen, Germany) combined with a laser unit providing a 
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pulsed nitrogen laser beam (wave length 337 nm) (Thalhammer et al. 2004). 
Depending on the sample material, laser energy and focus level were adjusted to create 
a laser spot size of a few micrometers for accurate particle isolation. This was 
supported by the use of a long distance objective (40x magnification) for adjusting the 
numerical aperture and therefore further optimize the microdissection procedure. The 
movement of the microscopic stage was controlled via joystick and the ‘Nanosauger’ 
software (XYZ High Precision, Darmstadt, Germany). 
For documentation a CCD camera (Rolera-XR Fast1394, Q Imaging, Surrey, Canada) 
mounted on the microscope and the Q Capture Pro 6.0 software (Q Imaging, Surrey, 
Canada) was used. 
 
 
4.4 Single particle transfer via SPATS  
 
Laser microdissected tissue samples or single cells were transferred horizontally via the 
low-pressure transfer system SPATS (single particle adsorbing transfer system) to the 
reaction centres of a planar PCR slide with a chemically-modified 
hydrophilic/hydrophobic surface structure (AmpliGrid, Advalytix-Beckman Coulter 
GmbH, Munich, Germany).  
The SPATS unit consists of a pressure supply unit PLI-100 (Havard Apparatus, 
Holliston, USA), a micrometer step motor arrangement, a sample-adsorbing head and 
the control software ‘Nanosauger’ version 2.5 (XYZ High Precision, Darmstadt, 
Germany) and is integrated into the inverted optical microscope (Fig. 2) (For detailed 
technical description and transfer procedure, see Woide et al. 2009). 
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Fig. 2: A) Schematic drawing of the SPATS system integrated to the inverted optical microscope 
(Axio Observer.Z1, Zeiss, Oberkochen, Germany). B) Detail of the adaptor arm including the sample-
adsorbing head.  
 
The sample-adsorbing head was designed to be disposable and consists of a 
transparent glass tube, a perforated copper disk and a copper grid (Fig. 3). The 
rectangular bending of the 100 mm long glass tube (Hirschmann Laborgeräte GmbH & 
Co.KG, Eberstadt, Germany) was done via a Bunsen burner to a ration of 25 to 75 mm. 
The outer diameter of the glass tube is 1.75 mm and the inner diameter is 1 mm. A 
perforated copper disk (Plano GmbH, Wetzlar, Germany) with 3.05 mm outer and 1 mm 
inner diameter was glued to the glass tube with a UV curing adhesive (Norland 
products, Cranbury, USA) and hardened under UV-light. Afterwards, the copper grid 
(Plano GmbH, Wetzlar, Germany) with an outer diameter of 3.05 mm and a mesh size 
of 5 µm was glued to the perforated disc as well and hardened under UV-light. This 
sample-adsorbing head was sterilized under UV-C irradiation and cleaned with ethanol 
for repeated use. 
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     Fig. 3: Picture of the sample-adsorbing head connected to the pressure supply unit via the    
     rotatable adaptor arm. The detail shows the sample-adsorbing head with the glass tube (a), the  
     perforated copper disk (b) and the copper grid (c). 
 
The transfer procedure is summarized as follows. The micrometer stepmotor allows 
movement of the sample-adsorbing head in xyz-direction necessary for the exact 
positioning and is controlled via the ‘Nanosauger’ software. After laser microdissection 
the sample and the sample-adsorbing head were first centred in the field of view. Then, 
the sample-adsorbing head was lowered to the glass slide and stopped a few 
micrometers above the isolated sample (Fig. 4 A). Low-pressure was started and the 
sample was adsorbed to the grid of the head (Fig. 4 B). In order to prevent loss of the 
sample, low-pressure was held during the transfer until the sample was released. The 
sample-adsorbing head was then removed from the slide surface and the sample was 
transferred to a reaction centre of the chemically-structured PCR slide. Low-pressure 
was stopped and the sample was released from the grid into a 300 nl sterile water 
droplet (Fig. 4 C) using a short high-pressure impulse. After the water droplet was dried 
at room temperature, the sample was located on the hydrophilic reaction centre of the 
PCR slide (Fig. 4 D). All preparative steps were performed under optical control.  
 
 
Fig. 4: Transfer procedure of a single particle via the single particle adsorbing transfer system SPATS A) 
Light microscopic image of a laser microdissected tissue sample (arrows) from a colon polyp. B) The 
isolated tissue sample is attached to the grid of the sample-adsorbing head. C) The tissue sample was 
released into a 300 nl droplet of sterile water on the reaction centre of a hydrophilic/hydrophobic 
structured PCR slide (AmpliGrid, Advalytix-Beckman Coulter GmbH, Munich, Germany). D) Isolated 
tissue sample at the surface of the PCR slide after the water was evaporated. 
 
 
4.5 Control DNA 
 
Genomic DNA was isolated from a whole peripheral blood sample of an unaffected 
male using the All-tissue DNA-Kit (Gen-ial GmbH, Troisdorf, Germany) according to 
manufacturer’s instructions. DNA concentration was determined using the Nanodrop 
ND-1000 Spectrophotometer (Peqlab Biotechnologie GmbH, Erlangen, Germany). The 
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genomic DNA solution was diluted into aliquots of 1 ng/µl, 250 pg/µl, 100 pg/µl, 50 pg/µl 
and 10 pg/µl. As a positive control, 1 µl of diluted DNA solution was pipetted to a 
reaction centre of the PCR slide and dried at room temperature.  
 
 
4.6 Analysis methods 
 
4.6.1 Polymerase chain reactions 
4.6.1.1 Low-volume multiplex PCR 
Low-volume (LV) PCR reactions were carried out in 1 µl total reaction volume covered 
with 5 µl mineral oil to prevent evaporation and external contamination (Fig. 5). The 
reaction mixture was placed in the reaction centres of the hydrophilic/hydrophobic 
structured PCR slide (AmpliGrid, Advalytix-Beckman Coulter GmbH, Munich, Germany; 
Fig. 5). After the amplification reaction PCR products from the slides were transferred 
into 0.2 ml reaction tubes and diluted 1:10 with sterile water.  
 
 
Fig. 5: Image of the planar PCR slide AmpliGrid A) Schematic drawing of the planar PCR slide with 
the hydrophilic (blue) and hydrophobic (yellow) structured surface. The hydrophilic reaction centre,  
1.6 mm in diameter, is covered with 1 µl PCR mixture. A hydrophobic ring around the reaction centre 
holds the mixture in place. The 5 µl mineral oil, which cover the PCR mix and prevent evaporation, 
are hold in place by a hydrophilic ring. B) Picture of one single droplet with a blue aqueous solution 
symbolizing the PCR mixture. C) Detail picture of the planar PCR slide with 48 reaction centres on 
the size of a normal object slide 76 mm x 25 mm x 1 mm.  
 
Primary PCR was performed using an AmpliSpeed slide cycler (Advalytix-Beckman 
Coulter GmbH, Munich, Germany) or an Eppendorf Mastercycler with in situ adapter 
(Eppendorf AG, Hamburg, Germany). All low-volume PCR reactions were carried out as 
multiplex PCR reactions using the QIAGEN® Multiplex PCR Kit (Qiagen GmbH, Hilden, 
Germany) accordingly to the basic protocol (Tab. 1). Primer concentrations were 
optimized for each patient-specific PCR reaction and according to the number of 
primers combined in one multiplex reaction.  
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Tab. 1: Basic protocol for low-volume multiplex PCR reactions 
Reagents 1x Final concentration 

















0.15 to 3.0 µM 
- 
 
Staining of the PCR mixture with Advablue or Advagold (Advalytix-Beckman Coulter 
GmbH, Munich, Germany) served as control in the low-volume reaction to exclude 
mixing of the master mix with the mineral oil during PCR. The staining was used only for 
the initial testing PCR reactions and not in sample analysis. Primer sequences and 
locations for the low-volume PCR reactions are listed in table 2 (colon polyps) and 3 
(patient-specific single cells). 
 
Tab. 2: Details on primer sequences for colon polyp analysis: Low-volume 6x multiplex PCR reactions 
were carried out with non-labelled primer pairs for the genes BRAF exon 15 and KRAS exons 2 and 3 
and for microsatellite markers BAT25, BAT26, BAT40. 
Primer Sequence (5’-3’) Location  
BAT25-F TCG CCT CCA AGA ATG TAA GT 4q12 
BAT25-R TCT GCA TTT TAA CTA TGG CTC  
   
BAT26-F TGA CTA CTT TTG ACT TCA GCC 2p21 
BAT26-R AAC CAT TCA ACA TTT TTA ACC C  
   
BAT40-F 
BAT40-R 
ATT AAC TTC CTA CAC CAC AAC 
GTA GAG CAA GAC CAC CTT G 
1p12 
   
Braf15-F-out TGC TTG CTC TGA TAG GAA AAT G 7q34 
Braf15-R-out TAA CTC AGC AGC ATC TCA GG  
   
Kras2-F-out CGT CTG CAG TCA ACT GGA AT 12p12.1 
Kras2-R-out AGA ATG GTC CTG CAC CAG TAA  
   
Kras3-F-out TTT TGA AGT AAA AGG TGC ACT G 12p12.1 
Kras3-R-out TGC ATG GCA TTA GCA AAG AC  
 
Tab. 3: Details on primer sequences for patient-specific single cell analysis: Low-volume 3x multiplex 
PCR reactions were carried out with primer pairs PC1-F/R for the 1 bp deletion of patient C and PD1-F/R 
for the 5 bp deletion of patients D and E.  
Primer Sequence (5’-3’) Mutation/location  
PC1-F GAA TAC TAC AGT GTT ACC CAG CTC c.2612delG 
PC1-R TCA GTG GTA GAC CCA GAA CTT  
   
PD1-F  
PD1-R 
CAG TTG AAC TCT GGA AGG CAA 
GGA GAA ACA CAT TCC TGC TGT C 
c.3183-3187delACAAA 
   
D5S346-F-FAM ACT CAC TCT AGT GAT AAA TCG GG 5q22-q23 
D5S346-R AGC AGA TAA GAC AGT ATT ACT AGT T  
   
D5S82-F-FAM ATC AGA GTA TCA GAA TTT CT 5q21.3 
D5S82-R CCC AAT TGT ATA GAT TTA GAA GTC  
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An overview of the LV-PCR conditions for colon polyp and patient-specific single cell 
analysis is given in table 4. The conditions were optimized for each multiplex primer 
combination. The cycle numbers in primary and secondary PCR depend on the total 
numbers of cycles in both reactions and were adjusted to the yield of secondary PCR 
product which was checked in gel electrophoresis. 
 
Tab. 4: Overview of PCR conditions for low-volume PCR reactions 
Analysis PCR step PCR conditions 









97°C 20 min 
94°C 30 s      | 
64°C* 30 s      | 15x 
72°C 30 s      | 
94°C 30 s      | 
50°C 30 s      | 23x 
72°C 30 s      | 
72°C   7 min 









97°C 20 min 
94°C 30 s      | 
64°C* 90 s      | 15x 
72°C 30 s      | 
94°C 30 s      | 
50°C 30 s      | 10x or 15x 
72°C 30 s      | 
72°C   7 min 
 
*temperature increment of -1°C per each cycle  
 
For the multiplex PCR with the three microsatellite markers D7S1824, D9S302 and 
D10S2325 exclusively a LV-PCR was carried out in contrast to the previously 
mentioned reactions. Primer sequences and locations of the microsatellite markers are 
shown in table 5. Modified conditions for this multiplex PCR are listed in table 6. 
 
Tab. 5: Details on primer sequences for single cell analysis: Low-volume 3x multiplex PCR reactions were 
carried out with primer pairs for the microsatellite markers D7S1824, D9S302 and D10S2325.  
Primer Sequence (5’-3’) Location  
D7S1824-F-HEX 
D7S1824-R 
GCA CCT GTT TGA TTC AGT CA 
CCA GCC TGT GTG ACT ATG TG 7q34 
   
D9S302-F-FAM 
D9S302-R 
GGG GAC AGA CTC CAG ATA CC 
GCG ACA GAG TGA AAC CTT GT 9q32 
   
D10S2325-F-FAM CTC ACG AAA GAA GCC TTC TG 10p13 
D10S2325-R GAG CTG AGA GAT CAC GCA CT  
 
Table 6: PCR conditions for low-volume PCR reactions with microsatellite markers 
Analysis PCR step PCR conditions 






97°C 20 min 
94°C 30 s      | 
61°C 60 s      | 37x 
72°C 30 s      | 
72°C   7 min 
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After the amplification reaction, PCR products from the slides were transferred into 0.2 
ml reaction tubes and diluted 1:6 with sterile water. One microlitre of this dilution was 
used directly for fragment length analysis. 
 
4.6.1.2 Nested PCR 
Aliquots of 1 up to 3 µl of each diluted sample of primary PCR were used as templates 
in secondary singleplex PCR reactions. PCR was carried out using the QIAGEN® 
HotStarTaq PCR Kit (Qiagen GmbH, Hilden, Germany) accordingly to the basic protocol 
(Tab. 7).  
 
Tab. 7: Basic protocol for secondary (nested) PCR reactions 
Reagents 1x Final concentration 
2x HotStarTaq Master Mix 
Sterile water 
Single primer pair 
Template (primary PCR product) 
 
Final volume 
6.0 or 12.5 µl 
variable 
0.5 or 1.0 µl 
1.0 to 3.0 µl 
 






Secondary PCR was performed using a Primus Advanced96 Peqlab Cycler (Peqlab 
Biotechnologie GmbH, Erlangen, Germany), a Cyclone25 Peqlab Cycler (Peqlab 
Biotechnologie GmbH, Erlangen, Germany), a DNA Engine Tetrad 2 Peltier Thermal 
Cycler, (BIO-RAD, Munich, Germany) or a DYNAD DNA Engine Peltier Thermal Cycler 
(MJ Research Minneapolis, USA). Primer sequences and analysis methods used are 
listed in table 8 (colon polyps) and 9 (single cells).  
 
Tab. 8: Details on primer sequences for colon polyp analysis: Nested PCR reactions were carried out with 
fluorescence-labelled primer pairs for microsatellite markers BAT25, BAT26, BAT40 and with non-labelled 
primer pairs for the genes BRAF exon 15 and KRAS exons 2 and 3. 
Primer Sequence (5’-3’) Analysis method 
BAT25-F-FAM TCG CCT CCA AGA ATG TAA GT Fragment length analysis 
BAT25-R-HEX TCT GCA TTT TAA CTA TGG CTC  
   
BAT26-F-FAM TGA CTA CTT TTG ACT TCA GCC Fragment length analysis 
BAT26-R-HEX AAC CAT TCA ACA TTT TTA ACC C  
   
BAT40-F-FAM 
BAT40-R-HEX 
ATT AAC TTC CTA CAC CAC AAC 
GTA GAG CAA GAC CAC CTT G 
Fragment length analysis 
   
Braf15-F-in CTT TAC TTA CTA CAC CTC AG Gel electrophoresis 
Braf15-R-in AGC ATC TCA GGG CCA AAA AT Sequencing analysis 
   
Kras2-F-in TTT TTA TTA TAA GGC CTG CTG Gel electrophoresis  
Kras2-R-in ATA TTA AAA CAA GAT TTA CCT C Sequencing analysis 
   
Kras3-F-in GGT GCA CTG TAA TAA TCC AG Gel electrophoresis  
Kras3-R-in ACT ATA ATT ACT CCT TAA TGT C Sequencing analysis 
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Tab. 9: Details on primer sequences for single cell analysis: Nested PCR reactions were carried out with 
primer pairs PC2-F/R for the 1 bp deletion of patient C and PD2-F/R for the 5 bp deletion of patients D 
and E.   
Primer Sequence (5’-3’) Analysis method 
PC2-F AGA ACG CGG AAT TGG TCT AGG CA Gel electrophoresis 
PC2-R TGA CTT TGG CAA TCT GGG CTG CA Sequencing analysis 
   
PD2-F  
PD2-R 
AAG ATG GGC AAG ACC CAA ACA C  
TGC TGT CCA AAA TGT GGT TGG 
Gel electrophoresis 
Sequencing analysis 
PD2-F-FAM AAG ATG GGC AAG ACC CAA ACA C    Fragment length analysis  
   
D5S346-F-FAM ACT CAC TCT AGT GAT AAA TCG GG Fragment length analysis  
D5S346-R AGC AGA TAA GAC AGT ATT ACT AGT T  
   
D5S82-F-FAM ATC AGA GTA TCA GAA TTT CT Fragment length analysis 
D5S82-R CCC AAT TGT ATA GAT TTA GAA GTC  
 
 
An overview of the secondary PCR conditions for colon polyp and single cell analysis is 
given in table 10. Variations of PCR conditions in cycle number and annealing 
temperature depend on different melting temperatures of the primers and were 
optimized for each primer pair during the establishment of the specific PCR system. 
 
Tab. 10: Overview of PCR conditions for nested PCR reactions 
Analysis Primers PCR step PCR conditions 















95°C          15 min 
94°C          30 s      | 
64°C*          30 s      | 15x 
72°C          30 s      | 
94°C          30 s      | 
50°C          30 s      | 15x or 20x  
72°C          30 s      | 
72°C            7 min 









95°C          15 min 
94°C          30 s      | 
59/62/64°C        60 s      | 25/x30x 
72°C          30 s      | 











95°C          15 min 
94°C          30 s      | 
57°C*          60 s      |   7x  
72°C          30 s      | 
94°C          30 s      | 
50°C          30 s      | 20x or 25x 
72°C          30 s      | 
72°C            7 min 
*temperature increment of -1°C per each cycle  
 
 
4.6.2 Gel electrophoresis 
Secondary non-fluorescence-labelled PCR products were separated on 2% agarose or 
10% polyacrylamide gels in order to control the presence and quality of amplification 
products.  
For agarose gel electrophoresis 5 µl of PCR solution were mixed with 3 µl of 6x loading 
dye (Peqlab Biotechnologie GmbH, Erlangen, Germany) and pipetted into the gel slots. 
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A 100 base pairs (bp) DNA ladder (New England BioLabs, Ipswich, USA) was used as a 
size standard. Gels were run in 1x Tris-acetate-EDTA buffer at 130 V for 30 to 40 min at 
room temperature. Agarose gels were ethidium bromide stained and analyzed with a 
camera detection system (Transilluminator, Peqlab Biotechnologie GmbH, Erlangen, 
Germany). 
For polyacrylamide gel electrophoresis a 10% CleanGel (ETC, Kirchentellinsfurt, 
Germany) was rehydrated in delect buffer (ETC, Kirchentellinsfurt, Germany) for 2 
hours according to the manufacturer’s instructions. A mixture of 1 µl PCR solution and 5 
µl of loading dye (1:20 dilution of 6x loading dye with delect buffer) was pipetted into 
each gel slot. The gel was run at 180 V for 40 min and at 390 V for 45 min at 15°C 
(GenePhor electrophoresis unit, Amersham Biosciences Europe GmbH, Freiburg, 
Germany). A 100 bp DNA ladder (New England BioLabs, Ipswich, USA) was used as a 
size standard. Polyacrylamide gels were silver stained with the DNA Silver Staining Kit 
PlusOne™ (GE Healthcare, Biosciences AB, Uppsala, Sweden) according to the 
manufacturer’s instructions. 
 
4.6.3 Fragment length analysis  
A 1 µl aliquot of secondary PCR or a dilution (variable, depending on the PCR reaction) 
containing fluorescence-labelled primers (FAM, HEX) was mixed with 12.7 µl of Hi-Di™ 
Formamide (Applied Biosystems, California, USA) and 0.3 µl of GeneScan™-500LIZ™ 
size standard (Applied Biosystems, California, USA) and prepared for analysis on an 
AB/Hitachi 3130xL Genetic Analyzer (Applied Biosystems, California, USA). Data were 
analyzed using GeneScan™ 3.1.2 and GeneMapper® v4.0 software (Applied 
Biosystems, California, USA). 
 
4.6.4 Sequencing analysis  
The PCR products for sequencing were cleaned using 96 filter plates (Multiscreen® 
PCR µ96, Millipore Corporate, Billerica, USA). The total volume of PCR solution (12-25 
µl) and 20 - 100 µl sterile water were added into the filter plate. The liquid passed the 
filter membrane with the help of a vacuum pump. Once the liquid was completely 
removed, the DNA was dissolved in 15-20 µl of sterile water and transferred into new 
PCR tubes or 96 well plates. Double-strand sequencing was performed with the 
BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, California, USA). 
Aliquots of the cleaned secondary PCR product were used as template for the 
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sequencing reaction (Tab. 11) which was performed on a Veriti 96 Well Fast Thermal 
Cycler (Applied Biosystems, California, USA).  
 
Tab. 11: Protocol for sequencing PCR reactions 
Reagents 1x Final concentration 
5x BigDye Buffer 
BigDye cycle terminator 
Sterile water 
Primers  
Template (secondary PCR product) 
 
Final volume 
2.0 µl  
0.5 to 1.0 µl  
variable 
0.2 or 1.0 µl 






0.3 or 1.5 µM 
- 
 
PCR conditions for the sequencing reaction are shown in table 12. Primers for 
sequencing analysis are shown in tables 8 and 9. The amount of template, primers and 
BigDye cycle terminator used depended on the yield of secondary PCR product which 
was checked in gel electrophoresis. 
 
Tab. 12: PCR conditions for sequencing reaction 






96°C    60 s 
96°C    10 s      | 
50°C      5 s      | 25x 
60°C    75 s      | 
  4°C          forever 
 
Products of the sequencing reaction were cleaned via sephadex plates (Sephadex® G-
50, Sigma-Aldrich; 96 plate Multiscreen® HTS, HV, Millipore Corporate, Billerica, USA). 
Sephadex plates were centrifuged for 5 min at 2570 rpm (910 rcf; Universal 320, Hettich 
Zentrifugen) for removing the water. The complete sequencing PCR solution and 10 µl 
of sterile water were pipetted onto the sephadex and centrifuged for 5 min at 2570 rpm 
into a new 96 PCR plate (Thermo-Fast® 96 Detection Plate, Thermo Scientific, 
Waltham, USA). Finally, 20 to 30 µl of sterile water were added and the plate was 
covered with septa (plate Septa 96-well, Applied Biosystems, California, USA). 
Sequencing was performed on the AB Hitachi 3730 DNA Analyzer (Applied Biosystems, 
California, USA) according to the manufacturer’s instructions. Data were analyzed using 





5.1 Characterization of colon polyp tissue  
 
5.1.1 Analysis of mutations in the genes BRAF and KRAS 
Mutations in exon 15 of the BRAF gene and in exons 2 and 3 of the KRAS gene were 
analyzed using three colon polyp tissue sections from two patients. Characterization of 
colon polyps with regard to the two proto-oncogenes BRAF and KRAS involved in 
colorectal cancer development is important for a better molecular understanding of this 
disease. Information about identification of mutations in the polyp tissue and their 
localization can be integrated into an increasingly more specific classification of colon 
polyps. Combination with histological and clinical features enables deeper insights into 
tumour development. 
For One- and Three-letter-code of amino acids used in the text and RNA codon table 
see appendix. 
 
Patient A, Polyp 2320-08-IV 
After histological characterization of the hematoxylin and eosin (HE) stained tissue 
section, parts of polyp 2320-08-IV were classified as hyperplastic tumour tissue (Fig. 6 
A). Comparison of the HE stained section with the unstained tissue section enabled 
collection of samples from only the hyperplastic tissue area by means of laser 
microdissection (Fig. 6 B). Samples of different sizes were collected from the tissue 
section; these samples contained between 10 and 70 cells on average (Fig. 7). 
Determination of the exact number of cells or cell nuclei in one sample is not possible, 
as the 6 µm thick tissue section does not contain cells in a regular monolayer. It is 











Fig. 6: Colon polyp 2320-08-IV of patient A. A) Image of the HE stained tissue section. The 
hyperplastic tissue parts of the polyp are highlighted. B) Image of the unstained tissue section used 




Fig. 7: Detail of polyp 2320-08-IV of patient A. A) Image of the HE stained tissue section with two 
samples highlighted. B) and C) Detail images of laser microdissected samples using the unstained tissue 
section. Comparing the sizes of the two samples with the HE stained tissue section enables counting the 
average number of cells in these isolated samples. Sample B contains 10 and sample C about 70 cells. 
There is no complete correspondence of the samples in both tissue sections because the tissue sections 
were gained from different levels of the fixed tissue block.   
 
Sequencing analysis resulted in the detection of 10 different mutations in polyp 2320-
08-IV (Tab. 13).  
 
Tab. 13: Mutations of polyp 2320-08-IV of patient A 
Gene Mutation Codon Position  










































































*mutations at the amino acid position with another amino acid substitution are known 
 
The well-known hotspot mutation c.1799 T>A, p.Val600Glu in exon 15 of the BRAF 
gene was detected in 10 samples (Fig. 8). Mosaic forms of this activating mutation 
dominated in polyp 2320-08-IV and in only one of the 10 samples (10.0%) was the 
mutation fully manifested. In the overview there is no directed distribution in the 
appearance of the mutation from the inside to the outside of the polyp tissue or the 






Fig. 8: Schematic drawing of colon polyp 2320-08-IV of patient A. A) The distribution of the hotspot 
mutation c.1799 T>A, p.Val600Glu in exon 15 of the BRAF gene within the polyp tissue section is shown 
in an overview. The mutation was detected in the range of different forms of mosaicism (T>>A, T>A, T=A, 
A>T, A>>T) to the fully manifested mutation (A; mut). Samples with the wild type (T; wt) form of the gene 
are shown in dark green. B) displays the localization of all mutations found in the genes BRAF exon 15 
and KRAS exons 2 and 3. Samples carrying a mutation can be identified using the colour table. If a 
sample is stained in one colour for one mutation, this means that the sample is wt for the two other exons 
analyzed. Otherwise, samples are stained in more than one colour. Circled samples in A and B show the 
comparison of the BRAF hotspot mutation status with the other mutations in BRAF and KRAS found in 
the same sample. Sequence data are shown in figure 9 and detailed information on all mutations is listed 
in table 13.  
 
Compared to 10 samples displaying the mutation, sequencing analysis revealed 13 wild 
type samples in the polyp tissue section. Figure 8 B shows the distribution of all other 
mutations in BRAF and KRAS detected in the polyp tissue. Sequence data of polyp 
2320-08-IV mutations are shown in figure 9. One of the 13 samples carried the mutation 
c.1804 T>C, p.Ser602Pro in exon 15 of the BRAF gene as well as the mutation c.229 
G>T, p.Gly77Cys in exon 3 of the KRAS gene. Compared to the samples with the 
c.1799 T>A, p.Val600Glu mutation in figure 8 A it is shown that there were two samples 
with mutations in both the BRAF gene and in one of the exons of the KRAS gene. One 
sample carried the mutation c.143 G>A, p.Gly48Glu and a mosaic form of the hotspot 
mutation. In the other sample, the hotspot mutation c.1799 T>A, p.Val600Glu was fully 
manifested. In addition, the KRAS exon 2 mutation c.7 G>A, p.Glu3Lys could be 
identified. For detailed sequence information on mosaic forms of the c.1799 T>A, 
p.Val600Glu mutation see figure 8 A. 
Two of the 10 mutations found in polyp 2320-08-IV were silent and do not result in an 
amino acid substitution. The ratio of transversions to transitions is 20.0% (2 of 10) to 
80.0% (8 of 10) so that there are four times more transitions than transversions. Except 
for the activating hotspot mutation c.1799 T>A, p.Val600Glu, most of the detected 
mutations are not yet described. Detailed information on all mutations for patient A is 






Fig. 9: Sequence data of all mutations found in the 2320-08-IV colon polyp of patient A. 
Mutations (arrows) in the genes BRAF exon 15 and KRAS exons 2 and 3 are manifested as 










Patient A, Polyp 4407/09 
A definite histological characterization of the HE stained tissue section of polyp 4407-09 
could not be obtained (Fig. 10 A). The polyp could be classified either as hyperplastic 
polyp or sessile serrated adenoma (SSA) or a mixture or a changeover of both, 
respectively. Nevertheless, an exact differentiation of tumour and normal tissue was 
possible (Fig. 10 A). Laser microdissected samples were isolated from all tumour tissue 
areas using the unstained tissue section (Fig. 10 B). 
 
 
Fig. 10: Colon polyp 4407-09 of patient A. A) Image of the HE stained tissue section. The tumour tissue 
parts of the polyp are highlighted. B) Image of the unstained tissue section used for laser microdissection. 
 
In polyp 4407-09, 33 mutations including the hotspot mutation c.1799 T>A, p.Val600Glu 
were detected in sequencing analysis (Tab. 14). In contrast to polyp 2320-08-IV, 8 of 44 
samples (18.2%) carrying the hotspot mutation displayed the full manifestation of the 
mutation. A dominant or regular distribution of the mutation or mosaic forms within the 
tumour tissue was, as in the first polyp, not observed (Fig. 11 A). In comparison to polyp 
2320-08-IV, the ratio of mutated to wild type samples had increased from 0.77 (10 to 







Tab. 14: Mutations of polyp 4407-09 of patient A 



















































































































































































































































*mutations at the amino acid position but with another amino acid substitution are known 
 
Four of these 32 samples carried more than one mutation referred to all mutations 
except the hotspot BRAF mutation. The first sample, located in the upper left side of the 
polyp (Fig. 11 B) carried the mutations c.1807 C>T, p.Arg603X and c.1837 T>C, 
p.Leu613Leu in exon 15 of the BRAF gene as well as the mutation c.182 A>C, 
p.Gln61Pro in exon 3 of the KRAS gene. The second one, located in the lower left side 
of the polyp section (Fig. 11 B) carried the mutations c.1826 A>G, p.Gln609Arg and 
c.1850 T>C, p.Ile617Thr in exon 15 of the BRAF gene additionally to a mosaic form of 
the c.1799 T>A, p.Val600Glu mutation (Fig. 11 A). The third, very small sample 
displayed the mutations c.1820 C>T, p.Ser607Phe in exon 15 of BRAF, c.148 A>G, 
p.Thr50Ala and c.166 C>T, p.Leu56Phe in exon 3 of KRAS as well as the fully 
manifested c.1799 T>A, p.Val600Glu mutation. This sample is located in the lower right 




Fig. 11: Schematic drawing of colon polyp 4407-09 of patient A. A) The distribution of the hotspot 
mutation c.1799 T>A, p.Val600Glu in exon 15 of the BRAF gene within the polyp tissue section is shown 
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in an overview. The mutation was detected in the range of different forms of mosaicism (T>>A, T>A, T=A, 
A>T, A>>T) to the fully manifested mutation (A; mut). Samples with the wild type (T; wt) form of the gene 
are shown in dark green. B) displays the localization of all mutations found in the genes BRAF exon 15 
and KRAS exons 2 and 3. Samples carrying a mutation can be identified using the colour table. If a 
sample is stained in one colour for one mutation, this means that the sample is wt for the two other exons 
analyzed. Otherwise, samples are stained in more than one colour. Circled samples in A and B show the 
comparison of the BRAF hotspot mutation status with the other mutations in BRAF and KRAS found in 
the same sample. Sequence data are shown in figure 12 and detailed information on all mutations is 
listed in table 14.  
 
The mutations c.55 T>C, p.Leu19Leu in exon 2 and c.217 A>G, p.Arg73Gly in exon 3 of 
the KRAS gene were detected in the last of the four samples which is located in the 
lower right side of the tissue section. This sample additionally carried a mosaic form of 
the c.1799 T>A, p.Val600Glu mutation (Fig. 11). Six other samples displayed a mosaic 
or the fully manifested hotspot mutation beside a second mutation in exon 15 of BRAF. 
In seven cases the samples had mutations in one of the exons of KRAS and additionally 
carried the hotspot mutation. These samples are highlighted in figure 11. Two of 6 
samples isolated from the normal tissue area of polyp 4407-09 carried mutations. In one 
sample the mutation c.1843 G>A, p.Gly615Arg in exon 15 of the BRAF gene occurred 
and in the second sample the mutation c.81 T>C, p.His27His was detected in KRAS. 
As shown in table 14, seven of the 33 mutations are silent and in four cases nonsense 
mutations occurred, exclusively in the BRAF gene. A nonsense mutation is the 
exchange of an amino acid codon into a stop codon. The ratio of transversions to 
transitions for polyp 4407-09 is 21.2% (7 of 33) to 78.8% (26 of 33) which means there 
are 3.7 times more transitions than transversions. Detailed sequence data of all polyp 
























Fig. 12: Sequence data of all mutations found in the 4407-09 colon polyp of patient A. Mutations 
(arrows) in the genes BRAF exon 15 and KRAS exons 2 and 3 are manifested as mosaic or full 
mutation. For comparison, the corresponding wild type (wt) sequences are displayed.  
 
Patient A, Polyps 2320-08-IV and 4407-09 
For patient A, a total of 41 different mutations were detected of which 19.5% (8 of 41) 
were transversions and 80.5% (33 of 41) were transitions. The outcome of this is 4.1 
times more transitions than transversions. Furthermore, combining the results of both 
polyps, some mutations occurred at the same amino acid position but not (except one) 
at the same nucleotide. In each case two different mutations were detected at amino 
acid valine 600 (Val600Glu and Val600Asp), serine 607 (Ser607Ser and Ser607Phe), 
histidine 608 (His608Asp and His608Tyr) and glutamine 609 (Gln609X and Gln609Arg) 
in the BRAF gene. For the substitution of valine into aspartic acid two nucleotide 
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exchanges were necessary. The mutations at amino acid histidine 608 occurred at the 
same nucleotide c.1822. In one case the nucleotide was changed from C to G 
(His608Asp). In the second case the nucleotide changed from C to T (His608Tyr). Only 
this mutation occurred twice, once in polyp 2320-08-IV and once in polyp 4407-09. The 
silent mutation Leu613Leu occurred both in polyp 2320-08-IV and 4407-09 but at 
different nucleotides. In polyp 2320-08-IV, nucleotide c.1839 was changed from G to A 
and in polyp 4407-09 nucleotide c.1837 was changed from T to C.  
 
Tab. 15: Classification of all mutations of patient A 












































































































































































In the KRAS gene, two mutations occurred each at the amino acid threonine 50 
(Thr50Ala and Thr50Thr), alanine 59 (Ala59Val and Ala59Thr) and glutamic acid 63 
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(Glu63Gly and Glu63Glu). As a comparison with the analysis of genomic DNA of patient 
A revealed, all mutations are somatic. 
A major part of all detected mutations has not yet been described. The c.1799 T>A, 
p.Val600Glu mutation is known as an activating mutation in the hotspot region of exon 
15 of the BRAF gene (Davies et al. 2002 and Kumar et al. 2003). Lee and colleagues 
identified the mutation Asp594Gly (Swiss-Prot variant VAR_018624 in P15056) in non-
Hodgkin’s lymphoma, a variant of the mutation Asp594Tyr which was detected here at 
the same amino acid position Asp594 in the BRAF gene (Lee et al. 2003). The mutation 
c.1799,1800 T>A, G>T, p.Val600Asp (Swiss-Prot variant VAR_018628 in P15056) with 
two nucleotide substitutions was identified in a melanoma cell line (Davies et al. 2002). 
The mutation c.1827 G>T, p.Gln609His was identified in a malignant melanoma patient 
which is a variant of the two mutations at amino acid Gln609 detected in polyp 4407-09 
(Casula et al. 2004). In the KRAS gene the mutation Val14Ile (Swiss-Prot variant 
VAR_026109 in P01116) was identified in Noonan syndrome type 3 (Schubbert et al. 
2006). The mutation variant detected in polyp 4407-09 is a substitution of the amino 
acid valine to leucine at position 14. As mentioned before, two different mutations at the 
amino acid position alanine 59 in the KRAS gene were detected in the two polyps of 
patient A. The mutation Ala59Thr (Swiss-Prot variant VAR_016030 in P01116) was 
identified in a human transitional cell bladder carcinoma cell line and is classified as 
single nucleotide polymorphism (OMIM_190070_0004; NCBI assay ID: ss38341815) 
(Grimmond et al. 1992). The mutation Ala59Val identified in polyp 2320-08-IV is not 
described yet. At the amino acid position glutamine 61 in exon 3 of the KRAS gene two 
different mutations are described. The first mutation, Gln61Arg (Swiss-Prot variant 
VAR_036306 in P01116) was identified in a colorectal cancer sample and the second 
one, Gln61His (Swiss-Prot variant VAR_006841 in P01116; NCBI assay ID: 
rs17851045) was identified in lung carcinoma and is classified as a single nucleotide 
polymorphism (Fransén et al. 2004, Tam et al. 2006). The amino acid substitution from 
glutamine to proline (Gln61Pro) detected in polyp 4407-09 has not yet been described. 
Nine of the 41 mutations of patient A were silent mutations with no substitution of the 
amino acid. Eleven mutations were classified as benign, three as possibly damaging 
and 18 as probably damaging accordingly to the PolyPhen data base (http://genetics. 
bwh.harvard.edu/pph/)(Tab. 15). This internet tool characterizes amino acid 
substitutions according to a possible impact on the structure and function of a human 
protein. The PSIC (Position-Specific Independent Counts) value indicates how often an 
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amino acid substitution is observed in the protein family. Highly conserved amino acid 
positions are expressed in big values whereas less conserved positions are expressed 
in low values. For the two mutations Gln61Pro (ligand CAG) and Glu63Gly (ligand GNP: 
phosphoaminophosphonic acid-guanylate ester) the disruption of a ligand binding site of 
the Kras protein is predicted by PolyPhen. 
 
Patient B, Polyp 13342-f1 
On the basis of a HE stained tissue section one part of polyp 13342-f1 was classified as 
sessile serrated adenoma and another part as tubular adenoma (Fig. 13 A). Samples of 
several crypts were laser microdissected from the sessile serrated as well as from the 
tubular adenoma using the unstained tissue section (Fig. 13 B). 
In total, 6 different mutations were detected in both types of adenomas (Tab. 16). The 
hotspot mutation c.1799 T>A, p.Val600Glu occurred only in the SSA but not in the 
tubular adenoma of the polyp (Fig. 14 A). Of 9 mutated samples in the SSA, three 
displayed the fully manifested mutation, the other 6 samples mosaic forms of it. As in 
the polyps of patient A, a dominant distribution of the hotspot mutation from the bottom 
to the top of the crypt or the other way round was not observed. In the SSA, 9 wild type 
samples were detected so the ratio between mutated and wild type samples is 1:1.  
 
 
Tab. 16: Mutations of polyp 13342-f1 of patient B 













































Exon 3 G>A GAG>GAA c.228 Glu76Glu silent  Transition unknown 
 
An overview of the other 5 mutations in polyp 13342-f1 is given in figure 14 B. Only the 
silent mutation c.57 G>A, p.Leu19Leu was located in one crypt of the SSA. All other 
samples in the SSA showed wild type sequences for exons 2 and 3 of the KRAS gene. 
In the tubular adenoma 6 samples with 4 different mutations were detected. In one crypt 
3 of 5 samples carried the mutation c.32 C>T, p.Ala11Val, the two other samples had 
wild type sequences for exons 2 and 3 of KRAS. In the second crypt two samples each 







Fig. 13: Colon polyp 13342-f1 of patient B. A) Image of the HE stained tissue section. The tumour tissue 
parts of the polyp are highlighted. a) sessile serrated adenoma, b) tubular adenoma. B) Image of the 
unstained tissue section used for laser microdissection. 
 
 
Fig. 14: Schematic drawing of colon polyp 13342-f1 section of patient B. A) The distribution of the hotspot 
mutation c.1799 T>A, p.Val600Glu in exon 15 of the BRAF gene within the polyp tissue section is shown 
in an overview. The mutation was detected in the range of different forms of mosaicism (T>>A, T>A, T=A, 
A>T, A>>T) to the fully manifested mutation (A; mut). Samples with the wild type (T; wt) form of the gene 
are shown in dark green. B) displays the localization of all mutations found in the genes BRAF exon 15 
and KRAS exons 2 and 3. Samples carrying a mutation can be identified using the colour table. If a 
sample is stained in one colour for one mutation, this means that the sample is wt for the two other exons 
analyzed. Otherwise, samples are stained in more than one colour. Circled samples in A and B show the 
comparison of the BRAF hotspot mutation status with the other mutations in BRAF and KRAS found in 
the same sample. Sequence data are shown in figure 15 and detailed information on all mutations is 
listed in table 16.  
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In total, 3 of 6 mutations were silent and the ratio of transversions to transitions is 16.7% 
(1 of 6) to 83.3% (5 of 6) so there are almost 5 times more transitions than 
transversions. Nonsense mutations or different nucleotide exchanges at the same 
amino acid position were not observed. All mutations in polyp 13342-f1 were somatic 
mutations which resulted from the analysis of normal tissue of patient B. Sequence 
information on all mutations of patient B are shown in figure 15. 
 
 
Fig. 15: Sequence data of all mutations found in the 13342-f1 colon polyp of patient B. Mutations 
(arrows) in the genes BRAF exon 15 and KRAS exons 2 and 3 are manifested as mosaic or full 
mutation. For comparison, the corresponding wild type (wt) sequences are displayed.  
 
Except for the activating c.1799 T>A, p.Val600Glu mutation (Davies et al. 2002 and 
Kumar et al. 2003), the other 5 identified mutations of patient B are not described. Two 
of the mutations were classified as possibly damaging and one mutation was classified 
as probably damaging according to PolyPhen (Tab. 17). 
 
Tab. 17: Classification of the mutations of patient B 






























5.1.2 Analysis of microsatellite instability 
Microsatellite instability (MSI) status was analyzed using the three microsatellite 
markers BAT25, BAT26 and BAT40. Additionally, immunohistochemical staining of the 
MLH1 protein was performed. Defects in the mismatch repair gene MLH1 can cause 
microsatellite instability and additionally may be responsible for mutations in some 
genes e. g. genes important for cell cycle regulation. Therefore, analysis of 
microsatellite instability status is an important aspect of colon polyp classification. 
 
Patient A 
Fragment length analysis revealed fragment lengths of 122/117 bp (base pairs) for 
BAT25, 116/118 bp for BAT26 and 126/118 bp for BAT40 as wild type status for patient 
A (Fig. 16).  
 
Fig. 16: Fragment length analysis of the 
microsatellite markers BAT25, BAT26 and 
BAT40 of patient A.  Peak pattern show the 
wild type distribution of the different marker 
fragments. Arrows indicate the average 
fragment length of the markers: BAT25 
122/117 bp, BAT26 116/118 bp, BAT40 



















An overview of the microsatellite analysis for polyp 2320-08-IV is shown in figure 17 A. 
In total, 41 samples were analyzed of which two failed amplification (4.9%), 6 show 
microsatellite instability (14.6%) and 33 were microsatellite stable (80.5%). From the 6 
MSI samples, only one sample shows microsatellite instability in two of the three 
markers (MSI-high). In the other 5 samples only one of the three markers was unstable 
(MSI-low). Five of six MSI samples were localized at the top of the crypts or at the outer 
side of the polyp tissue, respectively. Comparison of the marker analysis with the 
immunohistochemical staining of the MLH1 protein showed a good concordance of the 
results (Fig. 17). MLH1 analysis revealed that about 90% of the cells were positive for 
the presence of the MLH1 protein (Fig. 17 B) and 80.5% of all analyzed samples were 
microsatellite stable. The assumption that presence of the MLH1 protein causes 
microsatellite stability (MSS) of the tumour tissue was thus confirmed.  
Figure 18 A shows an overview of the microsatellite analysis for polyp 4407-09 of 
patient A. In total, 113 samples of the polyp were analyzed. Ninety-eight samples were 
microsatellite stable (86.7%), 13 show microsatellite instability (11.5%) and two failed 
amplification (1.7%). In 6 of 13 MSI samples, only one of the three markers was 
unstable (MSI-low). The other 7 samples show microsatellite instability in two of the 
three markers (MSI-high). All of the 7 MSI-high samples were localized at the top or 
almost at the top of the crypts. Four of the MSI-low samples were localized at the 
middle part of the crypts and two of them were even localized at the bottom of one 
crypt. MLH1 immunostaining shows positive staining of about 80% of the cells which 
means presence of the MLH1 protein (Fig. 18 B). Compared to the marker analysis 
(86.7% MSS), a high concordance of the results was obtained (Fig. 18). In the detail 
image of MLH1 staining of polyp 4407-09 single cells can be differentiated (Fig. 19). 
Dark brown (positive) stained cell nuclei at the bottom of a crypt are clearly visible (Fig. 
19 a). The cells become lighter brown when the distance to the top of the crypt is 
reduced. Between these brown coloured cells some blue stained (negative) ones are 
identifiable (Fig. 19 b) which may be a template for microsatellite instability. Non-mitotic 






Fig. 17: Analysis of microsatellite instability of polyp 2320-08-IV of patient A. A) Results of fragment 
length analysis of the microsatellite markers BAT25, BAT26 and BAT40. Light brown: at least one of the 
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three markers shows microsatellite stability (MSS), results for one or two of the markers failed; brown: 
MSS; light blue: one of the three markers shows microsatellite instability (MSI-low); dark blue: two or 
three markers show MSI-high. B) Immunohistochemical staining of the MLH1 protein. Brown staining of 
nuclei means presence and blue staining means absence of the MLH1 protein in the cell. Positive 
staining is shown in 90% of the cells in the tumour tissue area.  
 
 
Fig. 18: Analysis of microsatellite instability of polyp 4407-09 of patient A. A) Results of fragment length 
analysis of the microsatellite markers BAT25, BAT26 and BAT40. Light brown: at least one of the three 
markers shows microsatellite stability (MSS), results for one or two of the markers failed; brown: MSS; 
light blue: one of the three markers shows microsatellite instability (MSI-low); dark blue: two or three 
markers show MSI-high. B) Immunohistochemical staining of the MLH1 protein. Brown staining of nuclei 
means presence and blue staining means absence of the MLH1 protein in the cell. Positive staining is 
shown in 80% of the cells in the tumour tissue area.  
 
 
Fig. 19: Detail of figure 18 B. 
Immunohistochemical staining of 
the MLH1 protein. a) The arrow 
indicates the brown staining 
which represents the presence of 
the MLH1 protein in the cell nuclei 
at the bottom of the crypt. b) The 
arrow indicates the predominantly 
blue rather than brown staining of 
the cell nuclei at the top of the 
crypt which means absence of 
the MLH1 protein in the cell. Non-
mitotic epithelial cells lack the 










For patient B, fragment length analysis revealed fragment lengths of 122/117 bp for 
BAT25, 116/118 bp for BAT26 and 126/119 bp for BAT40 as wild type status (Fig. 20).  
 
Fig. 20: Fragment length analysis 
of the microsatellite markers 
BAT25, BAT26 and BAT40 of 
patient B.  Peak pattern show the 
wild type distribution of the 
different marker fragments. 
Arrows indicate the average 
fragment length of the markers: 
BAT25 121/117 bp, BAT26 
116/118 bp, BAT40 126/119 bp. 














The results of microsatellite marker analysis for polyp 13342-f1 is shown in figure 21 A. 
Fifty-four samples of the polyp tissue were analyzed in total. Amplification failure 
occurred in 1.9% (1 of 54) of the cases, microsatellite instability was detected in 11.1% 
(6 of 54) of all samples and 87.0% (47 of 54) of the samples were microsatellite stable. 
In 5 of the 6 MSI samples only one of the three markers was unstable (MSI-low) and in 
one sample microsatellite instability in two of the three markers (MSI-high) was 
detected. Two of the MSI-low samples, at the bottom of the crypt, are localized in the 
sessile serrated adenoma area of the polyp. The other four MSI samples are localized 
in the tubular adenoma area of the polyp, in the middle part or at the top of the crypts. 
Immunohistochemical MLH1 staining yielded about 90% positive stained cells for both 
the sessile serrated and the tubular adenoma (Fig. 21 B). A high concordance of the 
results of the marker analysis (87.0% MSS samples) and the MLH1 staining (90% 






Fig. 21: Analysis of microsatellite instability of polyp 13342-f1 of patient B. A) Results of fragment length 
analysis of the microsatellite markers BAT25, BAT26 and BAT40. Light brown: at least one of the three 
markers shows microsatellite stability (MSS), results for one or two of the markers failed; brown: MSS; 
light blue: one of the three markers shows microsatellite instability (MSI-low); dark blue: two or three 
markers show MSI-high B) Immunohistochemical staining of the MLH1 protein. Brown staining of nuclei 
means presence and blue staining means absence of the MLH1 protein in the cell. Positive staining is 
shown in 90% of the cells in the tumour tissue area.  
 
 
5.1.3 Comparison of mutation and microsatellite analysis 
When comparing the microsatellite marker analysis of all three polyps with the mutation 
analysis there is no explicit coherence of samples carrying a mutation and MSI. In polyp 
2320-08-IV of patient A, only one of three MSI-low samples carried a mutation in exon 3 
of the KRAS gene and a mosaic form of the hotspot BRAF mutation. The other two 
samples displayed a wild type sequence in the analyzed KRAS gene or the 
amplification failed in part, respectively (Fig. 22). In the second polyp of patient A, 4407-
09, there were only two MSI-low samples which displayed a mosaic form of the BRAF 
hotspot mutation. Four other samples, either MSI-low or -high, were analyzed as wild 
type for mutations in BRAF and KRAS (Fig. 23). In polyp 13342-f1 of patient B one of 
four MSI samples carried a mutation in exon 15 of the BRAF gene. Three wild type 
samples according to KRAS or the BRAF hotspot mutation showed MSI-low or -high 
(Fig. 24). Only samples which gave results in at least two of all three parts of analysis 
were taken into consideration. 
An efficiency of 97.6% (203 of 208) for microsatellite marker analysis after low-volume 
(LV) multiplex polymerase chain reaction (PCR) was achieved for all three colon polyps. 
In only 2.4% (5 of 208) of all cases, none of the three microsatellite markers was 
amplified. In contrast, the efficiency for sequencing analysis was slightly lower with 
79.8% (166 of 208). The amplification failed in 42 of 208 (20.2%) cases when none of 














Fig. 22: Comparison of mutation 
and microsatellite marker 
analysis of polyp 2320-08-IV of 
patient A. A) Distribution of the 
hotspot mutation c.1799 T>A, 
p.Val600Glu in exon 15 of the 
BRAF gene within the polyp 
tissue section. B) Localization of 
all mutations found in the genes 
BRAF exon 15 and KRAS exons 
2 and 3. C) Fragment length 
analysis of the microsatellite 
markers BAT25, BAT26 and 
BAT40. Samples which carry a 
mutation and are microsatellite 
































Fig. 23: Comparison of mutation and microsatellite marker analysis of polyp 4407-09 of patient A. A) 
Distribution of the hotspot mutation c.1799 T>A, p.Val600Glu in exon 15 of the BRAF gene within the 
polyp tissue section. B) Localization of all mutations found in the genes BRAF exon 15 and KRAS exons 
2 and 3. C) Fragment length analysis of the microsatellite markers BAT25, BAT26 and BAT40. Samples 







Fig. 24: Comparison 
of mutation and 
microsatellite marker 
analysis of polyp 
13342-f1 of patient B. 
A) Distribution of the 
hotspot mutation 
c.1799 T>A, 
p.Val600Glu in exon 
15 of the BRAF gene 
within the polyp tissue 
section. B) 
Localization of all 
mutations found in the 
genes BRAF exon 15 
and KRAS exons 2 
and 3. C) Fragment 
length analysis of the 
microsatellite markers 
BAT25, BAT26 and 
BAT40. Samples 
which carry a 
mutation and are 
microsatellite unstable 





























5.2 Mutation analysis of single cells  
 
5.2.1 Efficiency of low-volume multiplex PCR with fixed single cells   
The efficiency of a low-volume multiplex PCR combining the three microsatellite 
markers D7S1824, D9S302 and D10S2325 using fixed single cells was analyzed. In 
preliminary experiments the combination of the three markers for multiplex PCR was 
tested and optimized using genomic DNA of an unaffected male. In total, 153 laser 
microdissected diploid single cells of the same person were amplified. For each marker 
two alleles were expected; all together a total number of 918 (6x153) alleles could be 
obtained. A full profile of the three markers consisting of 6 alleles is shown in figure 25.  
 
Fig. 25: Results of fragment length analysis of the microsatellite marker PCR using fixed single cells. The 
full profile consists of 6 alleles, generated with the three primer pairs D10S2325: 116 bp/131 bp; 
D7S1824: 170 bp /174 bp and D9S302:  bp/179 bp. Size standard: orange peaks. 
 
The amplification efficiency ranged from 75.2 to 88.9% for each allele. On average, an 
amplification efficiency of 80.0% was achieved in the low-volume multiplex PCR (Tab. 
18). All 29 negative controls analyzed in fragment length analysis were negative for the 
expected alleles. In one negative control an additional allele at 264 bp was detected. A 
full profile with 6 alleles was obtained from all 9 positive controls with 100pg genomic 
DNA. 
 




170 bp/174 bp 
D9S302 
262 bp/266 bp 
D10S2325 
116 bp/131 bp Total 
Total number of  
analyzed cells 153 cells 153 cells 153 cells 918 alleles 
Negative 
amplifications % 
18.3           11.1 
(28/153)     (17/153) 
23.6           24.8 
(36/153)     (38/153) 
19.0           23.6 
(29/153)     (36/153) 
20.0 
(184/918) 
Amplified alleles % 81.7           88.9 (125/153)  (136/153) 
76.4           75.2 
(117/153)  (115/153) 
81.0           76.4 








5.2.2 Establishment of a single cell analysis system for patient-specific APC 
mutations 
For the establishment of single cell analysis, fixed cells of three patients carrying 
heterozygous germ line mutations in the adenomatous polyposis coli (APC) gene were 
used (patient C: c.2612delG, patient D and E: c.3183-3187delACAAA) (Fig. 26). 
In an initial experiment the amplification efficiency of stained (Giemsa) and unstained 
fixed single lymphocytes was compared. Twenty-two stained and 22 unstained cells of 
each of the patients C and D were amplified in a nested PCR reaction using the primer 
pairs PC1/PC2 and PD1/PD2 (see tables 3 and 9). The amplification efficiency of the 
nested PCR product was analyzed using agarose gel electrophoresis. For patients C 
and D, an amplification product of stained cells was obtained in 27.3% (6 of 22) of 
cases. In contrast, amplification efficiency of the unstained cells yielded 81.8% (18 of 
22) for patient C and 40.9% (9 of 22) for patient D. Only samples with an amplification 
product were used for sequencing analysis. In total, 24 samples of patient C and 15 
samples of patient D (stained and unstained) were sequenced.  
 
 
Fig. 26: Specific mutations in the APC gene of familial adenomatous polyposis (FAP) patients C, D and 
E. A) Sequencing shows the heterozygous 1 bp deletion (c.2612delG) (arrow) of patient C. Lane 1: wild 
type sequence of exon 15; lane 2: forward patient-specific sequence B) shows the wild type sequence in 
lane 1 and the heterozygous sequence with the 5 bp deletion (c.3183-3187delACAAA) (arrow) of patients 
D and E in lane 2 (forward).  
 
Sequencing analysis resulted in 17 homozygous samples for patient C including 10 wild 
type samples and 7 samples carrying the deletion c.2612delG. Two samples were 
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analyzed as heterozygous which means both the wild type and the mutated allele of 
patient C were detected in a single cell. Analysis failed in 5 of 24 samples.  
For patient D, sequencing analysis resulted in 11 homozygous samples of which 8 were 
wild type and three showed the deletion c.3183-3187delACAAA. Analysis failed in 4 of 
15 samples. Sequencing yielded very low heterozygosity rates of 10.5% (2 of 19) for 
patient C and 0.0% (0 of 11) for patient D which means that staining of the cells lead to 
high allelic drop out rates. In keeping with these results, only unstained cells were used 
in the following experiments.  
PCR conditions were optimized comparing different combinations of temperatures and 
types of PCR in first (LV-PCR) and secondary (nested) PCR. For each of the patients C 
and D, 16 cells per reaction condition were amplified. The primary PCR was carried out 
as ‘touch down’ (TD) PCR or as specific PCR with a 59°C annealing step. ‘Touch down’ 
PCR means a temperature increment of -1°C per each cycle starting at 64°C to 50°C 
and 25 cycles at 50°C (see Tab. 4). The specific PC R was carried out as described in 
table 6 but with an annealing step at 59°C for 90 s ec and 20 cycles. Secondary PCR 
was carried out either as TD or as specific PCR. An overview of the combinations for 
first and secondary PCR is given in figure 27. 
 
Fig. 27: PCR conditions and 
combinations in first and secondary 
PCR. TD: touch down PCR; 59°C: 









The results of the amplification efficiency for every PCR condition are listed in table 19. 
When comparing all results, it is obvious that the highest efficiency was achieved with a 
combination of TD PCR followed by a specific secondary PCR. Although a specific PCR 
followed by either another specific or a TD PCR yielded the same efficiency for patient 
C, the combination TD – specific PCR gave the best results for both patients and was 







Tab. 19: Amplification efficiency of single cell PCRs carried out with different combinations of PCR 
conditions. 
PCR conditions TD – TD TD - 59°C  59°C – TD  59°C – 59°C  
Patient C 87.5 % (14/16) 100% (16/16) 100% (16/16) 100% (16/16) 
Patient D 62.5% (10/16) 81.3 % (13/16) 50.0% (8/16) 37.5% (6/16) 
 
The results of sequencing analysis are summarized in table 20. For each condition and 
patient 16 cells were analyzed. In most cases, the heterozygosity rates were increased 
compared to the previous experiment with stained and unstained cells. Nevertheless, 
further optimization of PCR conditions including temperature, cycle number, primer 
design and combination were carried out in several experiments. 
 
Tab. 20: Results of the sequencing analysis of single cell PCRs carried out with different combinations of 




  TD – TD TD - 59°C 59°C – TD 59°C – 59°C 
Patient C wt  6 6 3 2 
 
mut  6 8 8 10 
 heterozygous  2 2 2 4 
 Heterozygosity 
rate % 14.0 (2/14) 12.5 (2/16) 15.3 (2/13) 25.0 (4/16) 
 failed 2 - 3 - 
Patient D wt 4 4 4 4 
 
mut 6 9 3 1 
 heterozygous - - 1 1 
 Heterozygosity 
rate % 0.0 (0/10) 0.0 (0/13) 12.5 (1/8) 16.7 (1/6) 
 failed 6 3 8 10 
 
In a final experiment, a multiplex PCR was performed for 22 and 21 fixed single 
lymphocytes and two negative controls for patients C and D respectively and for 65 
single cells and 19 negative controls for patient E. The mutation-specific amplification 
products were part of the initial nested PCR reactions. The amplification products of 
microsatellite marker PCR served as control for the detection of allelic drop out or 
contamination events. To detect patient-specific deletions, the PCR products were 
sequenced (Fig. 26). In addition to sequencing, fragment length analysis (patient D and 
E) was performed. Amplification efficiency of single cell PCR ranged from 77.3% to 
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93.8%, shown with gel electrophoresis and fragment length analysis. Heterozygosity 
rates between 72.2% and 100.0% were achieved. For the 5 bp deletion c.3183-
3187delACAAA (patients D and E) heterozygosity efficiency was determined for full 
profiles of the multiplex PCRs in fragment length analysis. The full profile for patient D 
(82.3%) consists of the alleles 118/120 bp (D5S346) and 137/142 bp (PD2-FAM), for 
patient E (57.4%) the alleles 111 bp/119 bp (D5S346), 137 bp/142 bp (PB2-FAM) and 
173 bp/179 bp (D5S82) (Fig. 28). All results of this single cell analysis are summarized 
in table 21. 
 
Fig. 28: Results of fragment length analysis of the multiplex PCR for patient E (c.3183-
3187delACAAA). The full profile consists of 6 alleles, generated with the three primer pairs D5S346: 
111 bp/119 bp; PD2-FAM: 137 bp (mutated)/142 bp (wild type) and D5S82: 173 bp/179 bp. Size 
standard: orange peaks. 
 
 
Tab. 21: Results of the final single cell analysis 
Patient/Loci Amplification % Heterozygosity % Contamination % Analysis method 
Patient C                                     
c.2612delG 77.3   (17/22)   81.3    (13/16) 0.0     (0/16) 
Gel electrophoresis    
Sequencing analysis 
Patient D                                      
c.3183-3187delACAAA 
90.5   (19/21)   72.2    (13/18) 0.0     (0/18) Gel electrophoresis    Sequencing analysis 
85.7   (18/21)   83.3    (15/18) 0.0     (0/18) Fragment length analysis 
Patient D                                         
D5S346 85.7   (18/21) 100.0    (18/18) 0.0     (0/18) Fragment length analysis 
Patient E                 
c.3183-3187delACAAA 93.8   (61/65)   83.6    (51/61) 0.05   (3/61) Fragment length analysis 
Patient E                
D5S346 89.2   (58/65)   93.1    (54/58) 0.02   (1/58) Fragment length analysis 
Patient E                           
D5S82 92.3   (60/65)   76.7    (46/60) 0.0     (0 /60) Fragment length analysis 
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6 Discussion                                                     
 
6.1 Characterization of colon polyp tissue 
 
Colorectal cancer (CRC) is the second leading cause of death amongst cancer 
syndromes in the general population (Robert Koch-Institut, Mäkinen 2007). This 
complex disease is classified according to clinical, histological, morphological and 
molecular features but still much work has yet to be done for further understanding of 
tumour development (Jass 2007). Colorectal cancer is mainly characterized by the 
occurrence of a variable number and different types of polyps throughout the colon. The 
histological and morphological characterization of colon polyps enables the 
determination of carcinogenesis risk in affected patients in many cases (Kirchner and 
Reu 2008). Despite improved diagnosis and therapy in recent years, several questions 
remain unsolved. In some cases unequivocal histological differentiation of the type of 
colon polyp is not possible (Holinski-Feder and Morak 2010). Molecular analysis of 
colon polyp tissue allows deeper insights into tumourigenesis of a single polyp. 
Important molecular features for classification include the analysis of the microsatellite 
instability (MSI) status and occurrence of mutations in the proto-oncogenes BRAF and 
KRAS (Boland et al. 1998, Garnett and Marais 2004, Kranenburg 2005, O’Brien et al. 
2006).  
In the first part of this work small tissue particles isolated from three colon polyp 
sections of two patients were analyzed simultaneously with regard to mutations in the 
BRAF and KRAS genes and the microsatellite instability status. 
Isolation of sample material was performed via laser microdissection from 6 µm thick 
unstained tissue sections of the colon polyps. The size of the isolated particles varied, 
containing cells between 10 and 70 cells per particle on average (Fig. 7). Estimations of 
the cell number were reached by comparison of stained and unstained tissue sections 
but determining the exact number was not possible. Furthermore, cell number variation 
may occur due to slightly deviant thickness of the tissue sections from one end to the 
other. Additionally, there is the possibility of isolating only parts of a cell as cells were 
not arranged in a monolayer within the section. Despite these reasons, successful 
analysis of samples containing approximately 10 or even less cells could be performed. 
Varying amplification efficiencies independent of particle size or cell number could be 
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observed. It is assumed that this is due to different quality of tissue sections influenced 
by the preparation procedure including fixation and subsequent removal of the paraffin. 
There is evidence of degradation and fragmentation of DNA caused by fixation with 
formalin or formaldehyde, respectively. The cross-linking of proteins and DNA within a 
cell caused by formaldehyde leads to DNA strand breaks; the average DNA fragment 
length which can be found in fixed tissue is approximately 300 bp (Lehmann and Kreipe 
2001, Hunt 2008). Therefore only short sequences were amplified in this work, although 
amplification failure cannot be completely avoided in doing so. The risk of additional 
degradation of DNA possibly caused by hematoxylin and eosin (HE) staining was 
excluded by the use of unstained tissue sections (Burton et al. 1998, Murray 2007). 
Hematoxylin stains negatively charged molecules like nucleic acids and eosin stains 
positively charged molecules including positively charged amino acids (Bova et al. 
2005). DNA isolation from such stained tissue sections is possible if the tissue is well 
preserved. Although there is no evidence of HE staining inhibiting polymerase chain 
reaction (PCR) directly, as a precaution, the problem was circumvented. Furthermore, 
visibility of tissue structures is dramatically reduced when using HE stained tissue 
sections without the cover slip which is necessary for laser microdissection (Bova et al. 
2005). For this reason, Bazan and colleagues added a droplet of oil directly onto the 
stained tissue section and visibility was increased when the oil spread over the slide 
(Bazan et al. 2005). However, this step is a source of increased contamination risk as 
the sample is in contact with the oil prior to analysis. Moreover, though applicable when 
performing laser pressure catapulting isolating the sample into a plastic cap, it is not 
applicable with the recently developed single particle adsorbing transfer system 
(SPATS; Woide et al. 2009) due to increased capillary forces between sample and 
slide. Therefore, unstained tissue sections, which also allow a high visibility and a good 
distinction of crypts and epithelium cells, were used in this work.  
An outstanding advantage of the horizontal particle transfer via SPATS is the reliable 
and precise transfer and release of sample material to the planar chemically structured 
PCR slide (Schmidt et al. 2005, Woide et al. 2007). The whole procedure is performed 
under optical control which facilitates easy identification of a sample on the PCR glass 
slide (Fig. 4). This is in contrast to isolation of single particles into plastic caps because 
retrieving of the sample is not guaranteed in every case (Schütze and Lahr 1998). 
Furthermore, horizontal transfer of laser microdissected sample material enables PCR 
analysis in 1 µl directly from fixed tissue particles. Due to selective isolation and transfer 
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of specific regions of interest, cross-contamination with cells of the heterogeneous 
neighbouring tissue can be circumvented. The following aspects and arrangements 
further reduced the risk of contamination. Ultra-violet light irradiation of the sample 
adsorbing head and the PCR glass slide ensured sterilization prior to isolation. 
Moreover, the sample adsorbing head of the transfer system was designed as 
disposable and was changed prior to isolation of different polyps (Woide et al. 2009). 
Fewer preparative steps, for example the use of unstained tissue sections and PCR 
directly from tissue samples, further reduce the risk of contamination. Naturally, 
appropriate laboratory equipment and cleaning procedures were used. 
A fundamental factor of this approach is performing PCR directly from formalin-fixed 
paraffin-embedded tissue material. In general, relatively large tissue areas are 
necessary for DNA extraction due to loss of genomic information, e. g. caused by 
incomplete lysis of the sample material (Bova et al. 2005). Integration of sample 
denaturation into the first PCR cycle, carried out at 97°C for 20 minutes, can circumvent 
this problem. Even the whole genetic information contained in very small samples is 
conserved and thus accessible for analysis. Mutations in only a few cells from one 
sample can be detected this way. This displays a great advantage as ‘dilution’ of 
mutation information below the detection limit can occur when an excess of wild type 
DNA is present in the sample (Bazan et al. 2005). 
Although DNA extraction of tissue sections is standard in almost all laboratories 
performing microdissection (Spirio et al. 1998, Umetani et al. 2000, Lehmann and 
Kreipe 2001, Calabrese et al. 2004), some groups have different approaches. Cawkwell 
and Quirke also used formalin-fixed tissue particles for direct analysis in PCR reactions. 
But in contrast to 10 or 70 cells used here, they isolated particles in the range of  
1-2 mm2 consisting of several hundreds of cells. Some droplets of water were applied to 
the region of interest of the tissue section. Until the tissue was dislodged from the glass 
slide the samples were transferred into a PCR tube via a pipette (Cawkwell and Quirke 
2000). Another approach is the direct use of proteinase K digested, laser capture 
microdissected sample material as template for PCR without any further washing step. 
Here as well, a high number of cells ranging from 500-1000 cells per sample were used 
as template (Dillon et al. 2001). For sensitive detection of mutations rarely occurring in 
only a few cells within the heterogeneous polyp tissue, it is important to isolate only a 
small homogeneous region of interest. Thus, the probability of containing cells carrying 
a mutation is strongly elevated compared to samples consisting of a high proportion of 
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wild type cells (Bazan et al. 2005). Giuffrè and colleagues could show that laser 
microdissected samples with approximately 150-500 cells achieved a significantly more 
specific result in microsatellite analysis when compared to hand microdissection. 
However, cell lysis prior to DNA extraction using proteinase K lasted 18 hours in that 
study (Guiffré et al. 2005). In contrast, PCR analysis was performed immediately after 
sample isolation using the combination of SPATS and low-volume (LV) PCR presented 
here. 
Combined low-volume and nested PCR raises the sensitivity and efficiency of analysis 
applicable for templates consisting of only few cells. PCR in smaller reaction volumes 
are significantly more sensitive and efficient when applicable to low amounts of template 
material compared to PCR in larger reaction volumes (Piyamongkol et al. 2003, Proff et 
al. 2005, Schmidt et al. 2005, Lutz-Bonengel et al. 2007). In the study of Roehrl and 
colleagues the efficiency of single cell PCR from stained and fixed tissue sections was 
investigated. DNA was extracted from the fixed sample material and PCR was 
performed in 50 µl. Efficiencies of 11 to 25% were achieved for single cell PCR and 
efficiencies of 26 to 33% were achieved when using clusters of 10-30 cells (Roehrl et al. 
1997). In another study, PCR efficiency was optimized for microsatellite marker analysis 
of fixed colorectal tissue samples using the markers BAT25, BAT26 and BAT40. DNA 
was extracted and 20 ng/µl of DNA were used as template for PCR. Reduction of 
fragment length revealed an amplification efficiency of 97% for the markers mentioned 
(Umetani et al. 2000). The efficiency of microsatellite marker analysis achieved with LV-
PCR was in the same range with 96.7 and 98.1% for patients A and B, respectively. In 
contrast, this high efficiency was obtained using fixed sample material directly for PCR 
without prior DNA extraction. Another basic difference of this work is the application of a 
multiplex PCR combining not only the three microsatellite markers but additionally 
primers for the genes BRAF and KRAS. 
The approach presented in this work combining laser microdissection, horizontal 
sample transfer and subsequent low-volume multiplex PCR is unique. Although 
multiplex PCR itself is a standard tool in analysis, it yet has not been applied to fixed 
tissue samples in a 1 µl PCR.  
 
Analysis of the colon polyps was performed in a simultaneous approach implicating 
direct sequencing of BRAF exon 15 and KRAS exons 2 and 3 and microsatellite 
fragment length analysis. Three tissue sections of patients A and B were characterized 
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in respect to genetic alterations by isolating small homogeneous regions from single 
crypts. 
Polyps 2320-08-IV and 4407-09 of patient A were classified as hyperplastic polyp and 
either hyperplastic polyp or sessile serrated adenoma (SSA) respectively (Fig. 6 and 
10). In this case a differentiation between the two types of polyps relying only on 
morphological features was extremely difficult. Distinction is not possible in all cases as 
overlapping of morphological structures sometimes occur. This example highlights the 
fact that integration of molecular analysis is a basic aspect of classification and 
diagnosis on colorectal polyps.  
In total, 41 different mutations were detected in the two polyps of patient A, of which 
only three have been described in the literature. For another 6 mutations, different 
nucleotide substitutions were described at the same amino acid positions detected here 
(Tab. 13 and 14). Other studies screening for mutations in BRAF and KRAS rarely 
detected some additional mutations besides the hotspot mutations in the sequenced 
exons (Davies et al. 2002, Lee et al. 2003, Sarkozy et al. 2009). This might occur, on 
the one hand, depending on the sample material and, on the other hand, due to limited 
sensitivity in detection when analyzing more than 1 ng of genomic DNA extracted from 
heterogeneous tissue samples (Grimmond et al. 1992, Fransèn et al. 2004). However, 
even when using a highly sensitive method like high resolution melting curve analysis 
such a high number of mutations besides the hotspot mutations in KRAS and BRAF had 
not been detected (Seth et al. 2009). 
The mutation c.1799 T>A, p.Val600Glu (in the following named V600E) in exon 15 of 
the BRAF gene leads to an amino acid substitution from valine to glutamic acid. This 
causes the constitutive activation of the protein which is part of the MAP-kinase 
signalling pathway responsible for cell proliferation, among other functions (Davies et al. 
2002, Garnett and Marais 2004). This mutation plays an important role in early 
tumourigenesis, especially in colorectal cancer (Yang et al. 2004, Young and Jass 
2006). The activating V600E mutation was detected in 10 samples of polyp 2320-08-IV 
and in 44 samples of polyp 4407-09 (Fig. 8 and 11). Considering the crypt structure, it 
was supposed that a specific distribution of the mutation within one crypt might have 
been observed. For example, if the mutation occurs in a mitotic stem cell at the bottom 
of a crypt the clones of this cell were assumed to carry the same mutation too. So the 
mutation should have been detected along the crypt in almost every cell from the 
bottom to the top. Due to relatively slight deviations in the crypt structure of hyperplastic 
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polyps compared to normal polyps (Young and Jass 2006, Mäkinen 2007), a similar 
mutation detection was expected, at least in polyp 2320-08-IV. However, a predominant 
distribution of the mutation within the tissue section could not be observed in either 
polyp. The V600E mutation was detected in different regions of the polyp tissue not 
limited to either the top or bottom of crypts. In several samples a mosaic form of the 
mutation was manifested (Fig. 3 and 6, for mosaic forms see colour legend). Mosaic 
means that not all cells of a sample carry the mutation and/or that cells are either 
heterozygous or homozygous related to the mutation. Interestingly, in one case the fully 
manifested mutation was detected in one sample (polyp 2320-08-IV) right next to 3 wild 
type samples (Fig. 8). A fluent changeover from wild type to mutated samples was not 
observed. Considering these results it can be concluded that the mutation V600E 
occurs spontaneously in several cells throughout the polyp tissue independently from 
one another. Notably, besides the V600E hotspot mutation, a large number of mutations 
in exon 15 of the BRAF gene as well as in exons 2 and 3 of KRAS were detected. Most 
of these mutations were not described yet. This could be due to the fact that only 
samples with less than 100 cells were analyzed in this work. Usually, when large 
samples with heterogeneous cell populations were analyzed, genetic information of few 
cells cannot be detected as this is below the detection limit (Bazan et al. 2005). 
Remarkably, some of these mutations occur at the same amino acid position but not at 
the same nucleotide (Tab. 13 and 14). Comparing both polyps of patient A, each had a 
different mutation pattern independent from one another. Only one mutation, a C to T 
transition at histidine 608 occurred at the same nucleotide c.1822 in both polyps.  
Interestingly, in two samples from a crypt of polyp 4407-09 which was classified as 
normal, the mutations Gly615Arg in exon 15 of BRAF and His27His in exon 2 of KRAS 
were detected (Fig. 10 and 11). This might display a beginning process of 
tumourigenesis before histologically normal tissue develops aberrant crypt structures. 
The genetic cause for these results, if the mutations are important for tumourigenesis or 
are only by-products of cells with a deficient repair system, has to be investigated 
further. 
 
Recently, several studies verified that mutations in BRAF and KRAS are mutually 
exclusive in sporadic MSI CRC (Rajagopalan et al. 2002, Deng et al. 2004, Koinuma et 
al. 2004, Seruca et al. 2009). Although it is not discussed explicitly in every case, this is 
mostly related to the V600E mutation in BRAF and one of the hotspot mutations at 
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codons 12 or 13 (and perhaps codons 59, 61 and 63) of the KRAS gene (Seth et al. 
2009). Mutations in these codons of KRAS are associated with activation of the protein 
function as they are located in important ligand binding sites of the protein (Grimmond 
et al. 1992, Kranenburg 2005). Both genes are components of the MAPK-ERK 
signalling pathway and the activation of either BRAF of KRAS might be sufficient for 
activation of the pathway. However, it was demonstrated here that V600E occurred 
together with mutations in the KRAS gene in the same samples (Fig. 8 and 11). In one 
case, the V600E mutation was detected simultaneously with the mutation c.175 G>A, 
p.Ala59Thr, a well-known hotspot mutation of KRAS (Fig. 11; Swiss-Prot variant 
VAR_016030 in P01116; Grimmond et al. 1992). It might be possible that both 
mutations occurred in one cell as the analyzed sample consisted of relatively few cells. 
In the study of Seth and colleagues the G12D hotspot mutation of KRAS and the BRAF 
T529A mutation were detected in a cell line and therefore confirmed that both mutations 
occurred in the same cell (Seth et al. 2009). Regarding this result the authors suggested 
that it is likely that both mutations can occur in the same cell of primary tumour tissue. 
Despite these results, it cannot be excluded that the mutations Ala59Thr and V600E of 
patient A occurred in different cells of the sample as the mutations were detected as 
mosaic forms rather than fully mutated. 
In other samples of polyps 4407-09 and 2320-08-IV, mutations in codons 59, 61 and 63 
of the KRAS gene were found (Tab. 13 and 14). This demonstrated that hotspot 
mutations of BRAF (V600E, as shown previously for the polyps of patient A) and KRAS 
occurred in the same polyp of one patient. This is an extremely remarkable fact, as 
even patients having different polyps with either BRAF or KRAS mutations have shown 
to be a significantly rare event (Carvajal-Carmona et al. 2007). Furthermore, in three 
samples of polyp 4407-09 three mutations and, in one sample, four mutations were 
detected simultaneously. The first sample displayed the mutations Arg603X (X = stop 
codon) and Leu613Leu (silent) in exon 15 of the BRAF gene and Gln61Pro (hotspot 
codon) in exon 3 of the KRAS gene (Fig. 11). It can be assumed that a stop codon 
leads to more or less inactivation of BRAF whereas the mutation in codon 61 leads to 
activation of KRAS. This seems to be consistent with the hypothesis that mutations in 
BRAF and KRAS are mutually exclusive. In the second sample the mutations 
Gln609Arg, Ile617Thr and a mosaic form of V600E were found in exon 15 of the BRAF 
gene (Fig. 11). In this case it remains ambiguous if the entire protein would still be 
activated due to V600E when all of the three mutations might occur in the same cell. 
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The third sample carried a mosaic form of V600E additionally to the mutations 
Leu19Leu (silent) in exon 2 and Arg73Gly in exon 3 of the KRAS gene. Normally, silent 
mutations without amino acid substitution do not have any impact on the protein 
function. The four mutations Ser607Phe in exon 15 of BRAF, Thr50Ala and Leu56Phe 
in exon 3 of KRAS as well as the fully manifested V600E BRAF mutation were found in 
the fourth sample of polyp 4407-09. As visible in figure 11, this is a very small sample 
compared to others consisting of no more than 10 cells. Since sequencing analysis 
revealed a very good quality without background signals it is supposed that the mutation 
V600E could be present homozygously in (almost) every cell of the sample. 
In contrast to MSI CRC, simultaneous hotspot mutations of BRAF and KRAS were 
detected in sporadic primary carcinomas and lymph node metastasis of MSS CRC 
(Oliveira et al. 2007). Oliveira and colleagues found that increasingly more BRAF and 
KRAS mutations occurred exclusively in advanced tumours (T2-T4 according to the 
tumour-node-metastasis system) invading the muscularis propria and/or having spread 
into metastases. Synchronous mutations of BRAF and KRAS, in contrast, were never 
detected in the precursor lesions analyzed in that study. The colon polyps analyzed in 
this work had been classified as hyperplastic polyps and sessile serrated adenoma 
which are defined as precursor lesions prior to malignant transformation into 
carcinomas. Therefore, it is astonishing that BRAF and KRAS mutations occur 
simultaneously in these early stage polyps.  
 
One part of the polyp of patient B was classified as sessile serrated adenoma and the 
other part as tubular adenoma (Fig. 13). In total, 6 different mutations were detected in 
both parts, including the V600E mutation in BRAF (Tab. 16). In figure 14 it is clearly 
visible that the V600E mutation is limited to the SSA and is not present in the tubular 
adenoma. Another difference of both types is the distribution of the other mutations. In 
the SSA all samples were wild type for the KRAS gene except one silent mutation in 
KRAS (Leu19Leu in exon 2) in one sample. In contrast, in the tubular adenoma two 
mutations in both genes, KRAS and BRAF, were detected. In one crypt, almost all cells 
carried only the mutation Ala11Val in exon 2 of the KRAS gene (Fig. 14). This seems to 
be the result of clonal expansion of one mutated crypt stem cell as was expected 
previously for polyps of patient A. In another crypt of the tubular adenoma the mutations 
Lys591Arg and Arg603Arg in exon 15 of BRAF and Glu76Glu in exon 3 of KRAS were 
detected in different samples (Fig. 14). None of these mutations detected in the tubular 
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adenoma is a hotspot mutation either of BRAF or of KRAS. A striking aspect is the fact 
that half of the six mutations of patient B were silent mutations with no effect on protein 
structure and activity. In contrast, most of the mutations of patient A were missense 
mutations with possible effect on the protein structure or nonsense mutations. 
Additionally, a lower number of mutations was detected in patient B (6 mutations in 54 
samples, 11.1%) than in patient A (41 mutations in 154 samples, 26.6%). Nine of the 
eighteen samples of the SSA carried a mosaic form of V600E and in three of these the 
mutation was fully manifested (Fig. 14). A predominant distribution of the mutation 
related to the crypt structure could not be observed which is consistent with the results 
of patient A. This seems to confirm the thesis that the V600E mutation occurs 
spontaneously in different regions of the tissue of SSA or hyperplastic polyps. For 
statistically significant results, further studies need to be performed.  
 
The large number of mutations detected in the polyps raises the question as to what 
impact the mutations might have on protein structure and functionality. All mutations 
detected were somatic, which resulted from mutation analysis of DNA from the 
corresponding normal tissue or blood. Mutations at the hotspots of the BRAF and KRAS 
gene discussed above already cause the constitutional activation of the proteins and 
lead in the end to cell proliferation. Determining the effects of missense mutations which 
cause changes in the amino acid sequence is not simple. Chemical and structural 
features as well as protein functionality analysis are necessary for exact 
characterization of mutation effects. Generally, mutations which are related to ‘less 
important’ sites of the protein might have less impact on activity than mutations at the 
active centre. Compared to the results obtained from PolyPhen, mutations in KRAS 
exon 3 are more often classified as ‘benign’ when they are located away from the 
hotspot codons (Tab. 15). In contrast, mutations near the V600E mutation in exon 15 of 
BRAF are mostly classified as ‘probably damaging’ (Tab. 15). But reliable statements 
can be obtained only after protein analysis. In comparison, silent mutations do not 
change the amino acid sequence of a protein due to the degenerated genetic code (see 
One- and Three-letter-code of amino acids at the appendix). For almost all of the amino 
acids more than one combination of bases is available, which ensures a relatively high 
resistance against mutations.  
Compared to missense mutations, nonsense mutations always have negative effects 
related to the normal protein structure. If a stop codon is introduced into the coding 
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sequence of a gene, the translation of mRNA terminates before the end of the gene. 
The resulting mRNA is unstable in most cases when the stop codon occurs at least 50 
nucleotides upstream of the last splicing junction. In such cases, a nonsense-mediated 
mRNA decay is initiated and translation into proteins do not occur (Lykke-Andersen et 
al. 2001, Maquat 2005). In other cases a premature termination of mRNA translation 
leads to truncated proteins. The impact of such proteins is difficult to predict and 
depends on the final length and stability of the truncated protein and which domains are 
lost or affected. A truncated protein still can exhibit remaining functionality or binding 
capacity. In the worst case, this may result in a dominant negative effect, when the 
aberrant protein inhibits the function of normal wild type proteins and results in an 
actually recessive disorder being caused by a heterozygous mutation (Fearon and 
Vogelstein 1990). Another possibility is the nonsense-associated alternative splicing, 
where the exon containing the stop codon is skipped and a stable mRNA is generated 
(Wang et al. 2002). But in this case as well, the resulting protein structure is changed 
with an often unknown effect on protein function. 
Mutations generating stop codons occurred only in the BRAF gene of patient A whereas 
in the KRAS gene or in the polyp of patient B only missense or silent mutations were 
detected (Tab. 13, 14 and 16). 
 
Another important aspect is the question of possible causes of the mutations found in 
the polyps of patient A and B. A striking fact is that patient A exhibits a broad spectrum 
of mutations with no dominance for a specific base substitution or type of mutation. 
Presumably, deficiency in DNA repair might cause these mutations. Defects or silencing 
of the mismatch repair (MMR) gene MLH1 mainly lead to distinctive microsatellite 
instability which is not the case in either patient A nor B. Mutations or alterations in the 
MMR genes MLH1, MSH2, MSH6 and PMS2 causative for MMR deficiency furthermore 
induces an increase in point mutation frequency. However, investigations of 
premalignant precursor lesions (hyperplastic and adenomatous colorectal polyps) 
revealed that mutations in BRAF and KRAS precede silencing of the MMR gene MLH1 
due to hypermethylation in sporadic colorectal cancer (Seruca et al. 2009). 
Beside MMR genes, there are many other genes associated with DNA repair. Genes 
that are involved in base excision repair (BER) include OGG1 and MUTYH as well as 
further DNA glycosylases like UNG, SMUG1, MBD4 and TDG (Wood et al. 2001). Of 
these, OGG1 and MUTYH are responsible for removal and repair of 8-oxoguanine 
Discussion 78                                                                            
 
which mispairs with adenine (Boiteux and Radicella 2000). Deficiency in one of these 
two genes leads to an excess of G:C to T:A (G>T) transversions in several genes, e. g. 
in the adenomatous polyposis coli (APC) gene triggered by deficiency in MUTYH repair 
causing MUTYH-associated polyposis (Al-Tassan et al. 2002, Sampson et al. 2005). 
The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) removes 
methyl and alkyl groups from the O6 position of guanine (Wood et al. 2001). Silencing of 
this gene, e. g. by promoter hypermethylation results in an excess of G:C to A:T (G>A) 
transitions, for example in the proto-oncogene KRAS or the tumour suppressor gene 
TP53 (Esteller et al. 2001). 
Concerning the mutations of patients A and B, approximately four to five times more 
transitions than transversions can be observed. Although transversions are expected to 
occur more often due to the genetic code, a bias with an excess of transitions is 
observed in mammals. Transition rates depend on the amino acids affected and the 
nucleotide position in the codon (Brown et al. 1982, Collins and Jukes 1994). However, 
no prevalence of a specific base substitution like G to A transitions was detected in the 
polyps analyzed. Mutations occurred relatively equally at all three codon positions (Tab. 
13, 14, 16). If an alteration in any of the DNA repair genes is responsible for the point 
mutations in BRAF and KRAS, only further study of these genes will unravel the cause.  
 
In general, all three polyps of the two patients were primarily analyzed as microsatellite 
stable or low-grade MSI. Microsatellite instability is categorized as high-grade MSI (MSI-
H), low-grade MSI (MSI-L) and microsatellite stability (MSS) according to the criteria 
defined at the Bethesda workshop (Boland et al. 1998). Usually, a marker panel of five 
microsatellite markers is used for analysis. MSS means that none of the markers shows 
instability. MSI-L is defined as only one of the markers displays instability, and when two 
or more markers show instability the tissue is classified as MSI-H. Although only three 
markers (BAT25, BAT26 and BAT40) were analyzed in this work, classification was 
done according to the defined criteria.  
The results of microsatellite marker analysis showed good correlation with the 
immunohistochemical staining of the MLH1 protein. In polyp 2320-08-IV of patient A 
80.5% of the samples were MSS and immunohistochemistry revealed 90% positive 
staining. Samples of polyp 4407-09 were stable in 86.7% and MLH1 staining revealed 
80% positive staining of the tissue. For patient B, samples of polyp 13342-f1 showed 
MSS in 87.0% and immunohistochemical staining resulted in 90% positive stained cells. 
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Positive staining of the MLH1 protein means that the protein is present in the cells, 
which in turn leads to the expectation of microsatellite stability of the cells. Therefore, 
results of the immunohistochemical staining of MLH1 were confirmed by microsatellite 
marker analysis. 
Differentiation between MSS and MSI-L for the analyzed polyps is not simple, as a 
definition of the proportions of samples which show MSI and MSS is necessary. 
Usually, MSI is analyzed using genomic DNA extracted from tissue or tissue sections. In 
this way, the entire polyp tissue is characterized according to the size of the original 
sample. Giuffrè and colleagues demonstrated in their study that samples had to be 
reclassified when comparing the results of hand versus laser microdissected samples. 
The sensitivity of analysis increased as the size of the samples decreased. They also 
suggested that in some cases MSI occurs stepwise in relation to a proceeding MMR 
dysfunction but prior to the complete loss of MMR gene expression (Giuffrè et al. 2005). 
According to the results, all three polyps were classified as MSS or MSI-L. 
Microsatellite instability is a hallmark of mismatch repair deficiency in cells which can be 
achieved on two different ways: First, an inherited germ line mutation on one allele of a 
MMR gene and a somatic alteration on the second allele induce inactivation of the gene 
in patients with hereditary nonpolyposis colorectal cancer (HNPCC/Lynch syndrome). 
Second, hypermethylation of the promoter region of MLH1 leads to silencing of the gene 
in sporadic colorectal cancer (Lynch 1999, Toyota et al.1999). Patient A has inherited 
the functional allele of the MLH1 gene of her father. Therefore, the first possibility of 
MLH1 inactivation due to inherited germ line mutations can be excluded in this case. 
Mutation analysis of other MMR genes and analysis of the methylation status was 
performed neither for patient A nor patient B as this was out of scope of this work. 
However, according to the results of microsatellite marker analysis and 
immunohistochemical staining of MLH1 it is supposed that a high-grade CIMP (CIMP-H) 
associated with MLH1 promoter methylation can be excluded. But still the possibility of 
methylation of other genes or de novo mutations remains. 
 
Summarized, the BRAF hotspot mutation V600E was detected only in sessile serrated 
adenomas and hyperplastic polyps of both patients but not in the tubular adenoma. 
Mutations of BRAF and KRAS previously reported as mutually exclusive were detected 
in the same samples, even the V600E BRAF mutation and a hotspot mutation in KRAS. 
This might be due to a lower cell amount analyzed. A much higher number of mutations 
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was detected in the polyps of patient A than in the polyp of patient B. Most of the 
mutations from patient A were unclassified missense or nonsense mutations whereas 
the mutation pattern of patient B seems to be more innocuous except for the V600E 
mutation. The cause of point mutations may lie in DNA repair deficiency but must be 
investigated further. Microsatellite marker analysis and immunohistochemical staining of 
MLH1 revealed MSS or MSI-L of all three colon polyps.  
Both hyperplastic polyps and sessile serrated adenomas are generally referred to as 
‘serrated polyps’, although their biological relationship has not yet been clarified 
(Mäkinen 2007). Differentiation can be made between simple hyperplastic polyps, which 
were thought to have no malignant potential, and sessile serrated adenomas with 
evidence for malignant potential. These serrated polyps were thought to be the 
precursor lesions of the serrated pathway (Young and Jass 2006, Mäkinen 2007).  This 
pathway is integrated into the five molecular subtypes suggested for colorectal cancer 
classification (Jass 2007):  
1: CIMP-H, methylation of MLH1 resulting in MSI-H, associated with BRAF mutation  
2:  CIMP-H, partial methylation of MLH1 resulting in MSI-L or MSS, associated with 
BRAF mutation 
3:  CIMP-L, methylation of MGMT resulting in MSI-L or MSS, associated with KRAS 
mutation; chromosomal instability 
4:  CIMP-negative, no methylation and therefore MSS; chromosomal instability 
5:  CIMP-negative, inherited MMR deficiency resulting in MSI-H 
The first three subtypes can be summarized in the serrated pathway, responsible mostly 
for sporadic colorectal cancer. Main steps in this pathway include activation of the 
MAPK-ERK signalling pathway (via BRAF of KRAS), inhibition of apoptosis and 
silencing of specific genes by promoter hypermethylation facilitating MSI. A possible 
separation of the serrated pathway into sessile serrated and traditional serrated 
pathways was suggested depending on the affected gene (O’Brien et al. 2006, Mäkinen 
2007).  
In the sessile serrated pathway, an activating mutation in BRAF precedes methylation 
especially of MLH1 and/or MGMT. Silencing of MLH1 generates MSI-H and methylation 
of MGMT or partial methylation of MLH1 produces MSI-L (associated with groups 1 and 
2). Tissue alterations develop from the precursor lesions aberrant crypt foci to 
hyperplastic polyps to sessile serrated adenomas and finally, to serrated 
adenocarcinomas. 
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In the traditional serrated pathway, KRAS mutations precede methylation of MGMT and 
other tumour suppressor genes, followed by MSI-L or MSS (associated with group 3). 
Normal mucosa develops from aberrant crypt foci into hyperplastic polyps which may 
persist in an innocuous state or evolve into serrated adenomas and, in the end, to 
serrated adenocarcinomas. In both pathways, inhibition of apoptosis is initiated by 
methylation of genes responsible for cell cycle regulation. 
Comparison of the results obtained in this work with the suggested classification reveals 
similarities and differences. However, one must keep in mind that mainly molecular 
features were investigated and that for overall classification and diagnosis clinical and 
morphological features play an equally important role.  
The sessile serrated adenomas or hyperplastic polyp, of patients A and B respectively, 
harbour BRAF V600E mutations but the polyps were classified as either MSS or MSI-L. 
Mutations in BRAF and KRAS were demonstrated to be a very early event in 
tumourigenesis, preceding development of hypermethylation and MSI in sporadic CRC 
(Seruca et al. 2009). So if a sample carries the V600E BRAF mutation, methylation of 
MLH1 and the resulting MSI would be expected in the same sample rather than in a 
BRAF wild type sample. However, two BRAF wild type samples were classified as MSI-
H in polyp 4407-09 of patient A (Fig. 23). Although some samples displaying mutations 
(including V600E) in BRAF and/or KRAS were classified as MSI-L, other MSI-L or MSI-
H samples were wild type for BRAF and KRAS (Fig. 22-24). Correlations of MSI 
samples and samples carrying mutations were therefore not detected in this work. 
Possibly, overall MSI would have been developed in these polyps at a later stage if they 
had not been removed from the colon. Compared to the second subgroup (and the 
sessile serrated pathway), a partial methylation of MLH1 would also lead to low-grad 
MSI or microsatellite stability. Furthermore, the gradient occurrence of MSI was 
suggested by the incomplete loss of MLH1 function, which could be consistent with the 
MSS or MSI-L status of the analyzed polyps (Giuffrè et al. 2005). The CIMP status, 
which was not analyzed in these polyps, might provide further information about 
classification or chronological order of BRAF mutations and microsatellite instability.  
In the tubular adenoma of patient B, some mutations in BRAF and KRAS other than the 
hotspot mutations were detected. This result is consistent with the fourth subgroup 
according to Jass which also can be defined as the Vogelstein pathway or adenoma-
carcinoma sequence. Typical features of this pathway are mutations in the APC, KRAS 
or TP53 genes accompanied by chromosomal rather than microsatellite instability.  
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As mentioned previously and shown in several studies, mutations in BRAF and KRAS 
are mutually exclusive (Rajagopalan et al. 2002, Deng et al. 2004, Koinuma et al. 2004, 
Weisenberger et al. 2006, Seruca et al. 2009). It was demonstrated that BRAF V600E 
can be used as a molecular marker for sporadic CRC and is an exclusion criteria for 
HNPCC whereas KRAS mutations occur in sporadic as well as in inherited cancers 
(Domingo et al. 2005, Seruca et al. 2009).  
The results obtained in this work give rise to two different interpretations. First, they 
support the hypothesis that mutations in BRAF and KRAS are mutually exclusive in 
precursor lesions, as the mutation V600E and simultaneous mutations in codons 12 and 
13 of the KRAS gene were not found. Although a mutation in codon 14 of KRAS was 
detected, analysis of its effect on protein activity was outside the scope of this work 
(Tab. 14; Schubbert et al. 2006). Second, analysis of the three polyps revealed that 
mutations of BRAF and KRAS actually occur simultaneously, not only in one sample but 
in the same polyp of a patient. Furthermore, it has to be considered that mutations in 
BRAF and KRAS other than their hotspots occur simultaneously relatively often in the 
polyps analyzed. Usually, this mutation status was rarely detected, related not only to 
the hotspot mutations in BRAF (V600E) and KRAS (codons 12 and 13) but perhaps due 
to less sensitive analysis methods as mentioned previously (Samowitz et al. 2005). 
Therefore, this investigation demonstrated that sensitive and precise characterization of 
colon polyps should be a basic prerequisite for further research and understanding of 
CRC development. 
 
Based on the results examined so far, it can be assumed that the polyps of patient A 
were sporadic rather than inherited. However, considering the fact that the father of 
patient A harbours several polyps like SSAs or hyperplastic polyps in addition to the 
HNPCC syndrome, a genetic predisposition is suggested. A possible explanation for the 
development of polyps could be hyperplastic polyposis syndrome. Varying numbers and 
types of polyps are described by this syndrome, making a clear differentiation from 
other types of colorectal cancer difficult. Precursor lesions include hyperplastic polyps 
and sessile serrated adenomas which also can occur spontaneously and appear to be 
identical to those of hyperplastic polyposis (Minoo et al. 2006, Young and Jass 2006). 
Minoo and colleagues demonstrated that hypermethylation of multiple gene promoters 
in normal colorectal mucosa might be due to a genetic predisposition in hyperplastic 
polyposis (Minoo et al. 2006). It can thus be speculated if hypermethylation of certain 
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DNA repair genes could cause point mutations in several genes like BRAF and KRAS. 
In this case, mutations would be likely to appear throughout the polyp tissue, which 
might be supported by BRAF and KRAS mutations in normal mucosa of polyp 4407-09. 
This hypothesis may be confirmed by the findings of Carvajal-Carmona and colleagues 
who detected two polyps with V600E BRAF mutation and the G12C KRAS mutation in 
the surrounding normal mucosa (Carvajal-Carmona et al. 2007).  
 
These discrepancies reveal that much must be undertaken to further investigate the 
development and tumourigenesis of colorectal cancer. For patient A, future studies 
should focus on the familial aspect of cancer development, as it was shown that 
synchronous BRAF and KRAS mutations do not occur in sporadic MSS and MSI CRC 
precursor lesions. Although in this work analysis was limited to the BRAF and KRAS 
genes and microsatellite instability status, analysis of a large number of different types 
of polyps from many patients would give us a better insight into cancer development. 
For example, the characterization of the hyperplastic polyp (2320-08-IV) of patient A 
resulted in the detection of BRAF V600E which is associated with a certain cancer risk. 
However, hyperplastic polyps were thought to be innocuous for a long time. 
Characterization or even mapping of such polyps might reveal further understanding of 
tumourigenesis of these types of polyps and provide new insights especially into the 
serrated carcinogenesis pathway. In addition to molecular analyses, clinical information 
like family anamnesis, number and localization of polyps, age at diagnosis as well as 
morphological features are essential to cancer research and risk assessment for the 
patient. 
In this work it was shown that characterization or generation of a molecular map of 
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6.2 Mutation analysis of single cells 
 
Single cell analysis plays an important role in numerous fields of genetic testing, 
especially in preimplantation genetic diagnosis (PGD) (Ao et al. 1998, Klein et al. 1999, 
Lu et al. 2004, Peng et al. 2007). Recent years have seen a considerable increase in 
mutation analysis of monogenic diseases in the context of PGD due to advances in 
single cell analysis techniques. Up to now, mutation analysis of inherited monogenic 
disorders has been a well-established procedure (Kuliev et al. 2007, Renwick and 
Ogilvie 2007). As there is a need for validation prior to PGD, a test system is required to 
optimize the work flow, thus increasing the detection efficiency of mutations and to 
reduce allelic drop out (ADO). The precise and reproducible accessibility to single cells 
is a basic prerequisite to establishing such a test system. 
In an initial step, the efficiency of low-volume multiplex PCR using fixed lymphocytes 
was analyzed. LV-PCR was performed in a total reaction volume of 1 µl. Compared to 
PCR analysis in larger reaction volumes, this leads to an increased amplification 
sensitivity and efficiency of PCR which is necessary for minute amounts of DNA (Proff 
et al. 2005, Schmidt et al. 2005). Different combinations of microsatellite markers were 
tested using genomic DNA as template, and finally the markers D7S1824, D9S302 and 
D10S2325 fitted best in a multiplex reaction. As PCR was performed with these three 
fluorescence-labelled microsatellite markers, a single LV-PCR using fixed single cells 
yielded enough amplification products appropriate for analysis in fragment length 
analysis. In a statistical study the amplification efficiency of the six specific alleles for all 
three markers was analyzed in 153 heterozygous single cells of an unaffected male 
(Fig. 25). The average amplification efficiency of 80% with no value below 75% for each 
of the six alleles (Tab. 18) was near the range of fresh single cells, which demonstrated 
the sensitivity of LV-PCR appropriate for single cell analysis (Ray et al. 2001, Lee et al. 
2007, Spits et al. 2007). Additionally, a high specificity of the low-volume reaction was 
shown as in all 191 reactions (153 single cells, 9 positive and 29 negative controls) only 
one unspecific allele was detected. 
Although fluorescent LV-PCR yielded enough PCR products for successful fragment 
length analysis, the application of single cell amplification with subsequent sequencing 
analysis was tested. In sequencing analysis, the quality and type of mutations like 
deletions, insertions or single nucleotide substitutions can be detected. However, a 
higher yield of starting template is required for successful sequencing reactions which 
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turned out in serial experiments. Therefore, a nested PCR subsequent to the LV-PCR 
was introduced. The use of a nested PCR assay enables reducing the number of cycles 
during the first PCR and thus minimizes the risk of amplifying unspecific products. 
During the second PCR reaction, amplification products of the first PCR serve as 
template for the inner primers, and so the yield of specific amplification products 
increases. In further experimental steps specificity and sensitivity of LV- and nested 
PCR were increased gradually until PCR products were appropriate for direct 
sequencing.  
For a testing system for patients with specific mutations, microsatellite markers 
significant for the patients (C, D and E) and primers designed especially for their 
mutations (heterozygous germ line mutations c.2612delG and c.3183-3187delACAAA) 
were chosen (Tab. 3 and 9, Fig. 26). 
Visibility and recognition of stained single cells which were spread on a microscopic 
slide is markedly easier than identifying unstained cells. Due to a possible influence of 
staining on the PCR reaction, amplification efficiency was compared using stained and 
unstained fixed single lymphocytes of the patients. Gel electrophoresis of secondary 
PCR products revealed an obviously higher amplification efficiency of unstained (81.8 
and 40.9%) rather than stained (27.3%) cells. Discrepancy of amplification efficiencies 
between the two patients C and D of factor two can presumably be explained by the 
quality of the blood cells which may vary between several persons dependent upon their 
constitution. Samples from which PCR products were detected in gel electrophoresis 
usually produced a result in sequencing analysis independent of staining. However, 
heterozygosity rates for these samples were extremely low or even absent. In most 
cases, either the mutated or the wild type allele could be detected in one heterozygous 
cell.  
For this reason, PCR conditions had to be further optimized using exclusively unstained 
single cells. In the next approach differently combined conditions, ‘touch down’ or 
specific PCR in first or secondary reaction, respectively, were compared (Fig. 27). The 
advantage of specific PCR is the exact adjustment of the annealing temperature 
according to the melting temperatures of the primers used. For a singleplex PCR this is 
true but for a multiplex PCR with more than one primer pair slightly different melting 
temperatures sometimes cannot be avoided for several reasons. When designing 
primers an optimal length of about 20-25 nucleotides each, amplification of the chosen 
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DNA region with regard to the final product length and the nucleotide constitution of the 
specific sequence have been taken into account. 
The advantage of a touch down PCR is its higher specificity as stringency of primer 
binding is increased and unspecific binding can therefore be avoided. The annealing 
temperature of the first PCR cycle is chosen in relation to the highest melting 
temperature of all primers used. During the next 15 cycles the annealing temperature 
decreases by -1°C per cycle. Slightly different mel ting temperatures of the primers 
hence have only a lesser impact on efficiency. Therefore, it could be expected that 
performing a multiplex touch down PCR followed by a second specific singleplex PCR 
would yield in an optimal result which was confirmed by the analysis results of patients 
C and D. The highest amplification efficiency (100% and 81.3%) for both patients was 
achieved by combining the touch down with a subsequent specific PCR. Sequencing 
analysis revealed a trend for slightly higher heterozygosity rates of up to 16.7% 
compared to the previous approach yielded in 0 and 10.5%, but still were unacceptable 
for reliable single cell analysis. Application of fluorescent PCR, which is standard in 
PGD nowadays, as well as further optimization of PCR conditions and nested PCR 
protocols (concerning annealing temperature, cycle number and duration time, primer 
concentrations) were strategies for additionally increasing amplification efficiency and 
detection sensitivity in this work (Moutou and Viville 1999, Spits and Sermon 2009). 
 
Finally, the successful combination of single cell laser microdissection, single particle 
transfer and low-volume multiplex PCR is presented. It was shown that fragment length 
analysis and sequencing analysis could be performed on single cell PCR products. This 
approach displays not only the establishment of a genetic test system for single 
lymphocytes; analysis is also applicable to conventional isolated polar bodies, 
blastomeres or blastocyst cells which are transferred to a planar glass slide (Mayer et 
al. 2009). 
In comparison to other preliminary testing for PGD, some significant differences can be 
observed. The horizontal transfer of a series of isolated single lymphocytes via the 
SPATS system to a planar PCR slide constitutes a basic aspect in our approach. 
Optical control of the entire single cell handling including horizontal transfer ensures the 
reliability of the system in contrast to other isolation methods (Woide et al. 2009). A 
striking advantage is the use of easily accessible fixed single lymphocytes. Storage of 
fixed lymphocytes for several months in sufficient quality for PCR analysis allows 
Discussion 87                                                                            
 
repeated optimization experiments without the need for fresh blood samples. 
Considering the template DNA quality, primer pairs were chosen which amplify only 
short sequences no more than 200 bp in length. Furthermore, short fragments increase 
amplification efficiency and decrease allelic drop out in single cell PCR reactions 
(Piyamongkol et al. 2003).  
In contrast to the majority of investigations for PGD, in this approach heat denaturation 
of fixed lymphocytes was used prior to the first PCR cycle instead of chemical or 
enzymatic lysis of the cells (Spits and Sermon 2009). Higher denaturing temperatures of 
at least 96°C reduce ADO rates dramatically without  affecting amplification efficiency 
(Ray et al. 1996). Therefore, an initial denaturing step for single cell PCR of 97°C was 
chosen. This process enables time savings of up to 1 hour, depending on the lysis 
method, since the time needed for enzyme incubation or washing can be omitted. The 
overall time for the single cell analysis procedure, excluding laser microdissection, is 
about 8-12 hours, depending on which method is used, e. g. fragment length or 
sequencing analysis. Time is an important factor in PGD, and in polar body diagnosis 
analysis time is limited to about 20 hours in Germany (Tomi et al. 2005).  
Another advantage of heat denaturation is the reduced risk of contamination. Several 
lysis preparation steps and therefore unessential contact with potentially contaminated 
reagents or laboratory equipment can be avoided as the isolated cell on the reaction 
centre of the planar PCR slide is covered only with reaction mix and mineral oil before 
starting PCR. Precise isolation and transfer of only one single cell under optical control 
and dry conditions additionally ensures that the risk of co-isolation of contaminating 
particles such as cell debris or DNA which may be present in aqueous cell solutions is 
minimized. On the basis of PCR on a glass slide the possibility of releasing contaminant 
substances from plastic PCR tubes into the reaction mix, especially when the tube is 
heated, can thus be circumvented (McDonald et al. 2008). Contamination from other 
sources is reduced to a minimum due to extreme care and appropriate facilities in the 
laboratory.  
The combination of at least two polymorphic markers and a mutation-specific fragment 
ensure an accurate analysis of the heterozygosity status of a single lymphocyte cell. 
Such multiplex reactions not only allow the reliable detection of ADO but are an 
important element for indirect diagnosis with linked polymorphic markers. Although 
multiplex PCR exclusively carried out with polymorphic markers has the advantage of 
being applied to many patients with different mutations, we could show that a multiplex 
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assay combining different markers and mutation-specific primers can also be applied to 
several patients with the same mutation.  
Furthermore, this approach enables the possibility of direct analysis of specific 
mutations, as nested PCR of single cells yields enough DNA for sequencing analysis (if 
necessary). This could be the case if linkage analysis for polymorphic markers is not 
feasible for couples who wish to perform PGD (for review, see Spits and Sermon 2009). 
Whole genome single cell amplification which enables the combination of several 
different analysis methods such as mutation, polymorphic marker or STR analysis, 
comparative genomic hybridization (CGH) or fluorescence in situ hybridization (FISH) 
would display a great facilitation in PGD. Some efforts have been taken to establish 
whole genome amplification (WGA) of single cells for PGD and, as has recently been 
proven, multiple displacement amplification (MDA) using Phi29 polymerase is on its way 
to becoming the standard WGA method in PGD applications (Coskun and Alsmadi 
2007, Peng et al. 2007, Spits and Sermon 2009).  
However, there are still several problems to be resolved. For example, high ADO rates 
in the range of 20-30% achieved in subsequent PCR analysis using fresh cells can be 
by-passed only if a sufficient number of informative polymorphic markers is available 
(Spits and Sermon 2009, Glentis et al. 2009). This raises the same problems as 
mentioned for multiplex PCR when linkage analysis is not feasible. Another factor is the 
time that is needed for MDA reactions (up to 16 hours), especially when using 
commercially available WGA kits. Additionally, the time necessary for subsequent 
analysis also needs to be considered, as time constitutes an essential parameter in 
PGD. One possibility of increasing the sensitivity of MDA could be downscaling of the 
assay to low-volume reactions, which has proven to be successful for PCR. Yet, 
commercially available WGA kits are designed for larger volumes in the range of 50 µl 
and a prerequisite for downscaling is to adjust reagent concentrations and reaction 
conditions. For example, when MDA is to be performed on the planar glass slide, the 
compatibility of the reaction mixture with the covering mineral oil has been taken into 
account. In fact, single cell whole genome amplification resulting in a high DNA yield is 
a great advantage for PGD, as successful applications have shown (Glentis et al. 2009, 
Ren et al. 2009). 
In comparison with other PGD studies heterozygosity rates for polymorphic 
microsatellite markers and mutation-specific amplification products were achieved from 
fixed single lymphocytes in nearly the same range as those from fresh cells (Ray et al. 
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2001, Lee et al. 2007, Spits et al. 2007). Moreover, this single cell genetic test system 
was applied to polar body diagnosis for three female patients with mutations (a 1 bp and 
a 5 bp deletion, respectively; Fig. 26) in the APC gene mentioned above (diagnosis was 
done at the Medical Genetics Center). In five PGD cycles, polar bodies of 60 oocytes 
were analyzed and 13 of the oocytes were identified as normal. These polar body PGDs 
resulted in one clinical pregnancy. Although polar bodies enable the analysis of only the 
maternal genome, they nevertheless have some advantages. Polar body diagnosis is 
an adequate method applicable for inherited diseases in those couples where only the 
woman is affected. In addition, ADO rates are considerably less in polar body than in 
blastomere analysis and it is easier to find informative polymorphic markers, which can 
be important in challenging cases (Altarescu et al. 2008). Removal of cells from the 
embryo (as is the case in blastomere and blastocyst PGD) can also be circumvented.  
PGD of blastomeres where one or two cells are taken from the eight-cell stage embryo 
at day three postfertilization is still the method of choice in many laboratories (Spits and 
Sermon 2009). However, PGD of several trophectoderm cells extracted from the 
blastocyst stage of the embryo recently is becoming more important (McArthur et al. 
2005, Fragouli et al. 2009). Accuracy and reliability of analysis indisputably increases 
with the number of cells or template DNA, respectively, but even if, e. g., up to 10 cells, 
which together contain about 70 pg, were analyzed, this still lies within the range of 
minute amounts of DNA and requires sensitive analysis methods which the developed 
system provides (Lutz-Bonengel et al. 2007). There are many reasons for or against the 
use for both blastomere and blastocyst PGD. For example, advantages of 
trophectoderm cells, in contrast to blastomeres, include reduced ADO rates and 
amplification failure as well as higher implantation rates and approximately equal 
pregnancy rates (Pangalos et al. 2008). On the other hand, cryoconservation caused by 
the strictly limited time available for analysis has the potential to harm the embryo and 
prevent its implantation (McArthur et al. 2005, Spits and Sermon 2009). This problem 
could be overcome by applying the genetic test system to blastocyst cells as it was 
shown that analysis can be done within 12 h also necessary for polar body diagnosis. In 
fact, the application of polar body, blastomere or blastocyst PGD depends on several 
factors ranging from legal restrictions, and the genetic background of patients to the 
type of disease analyzed. However, it is clear that PGD will only ever be performed on 
few or single cells. 
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Thus, this investigation successfully validates reliable genetic testing for as little as one 
single cell by means of mutation detection in the APC gene.  
 
Moreover, the combination of single cell isolation, horizontal particle transfer and 
subsequent analysis can also be optimized for a wide range of other inherited diseases 
or genetic disorders and is not limited to polar bodies or PGD in general. This technique 
enables a variety of molecular analyses where isolation of few or single cells is 
important for genetic characterization. The whole analysis procedure performed in this 
work has proven to be successfully applicable for different questions in molecular 
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One- and Three-letter-code of amino acids and RNA codon table 
 
The table shows the 64 codons of the mRNA and the amino acids for each. The 
direction of the mRNA is 5' to 3'. Uracile (U) instead of thymine (T) is the corresponding 








UUU (Phe/F) Phenylalanine 
UUC (Phe/F) Phenylalanine 
UCU (Ser/S) Serine 
UCC (Ser/S) Serine 
UAU (Tyr/Y) Tyrosine 
UAC (Tyr/Y) Tyrosine 
UGU (Cys/C) Cysteine 
UGC (Cys/C) Cysteine 
UUA (Leu/L) Leucine UCA (Ser/S) Serine UAA Ochre (Stop) UGA Opal (Stop) 
UUG (Leu/L) Leucine UCG (Ser/S) Serine UAG Amber (Stop) UGG (Trp/W)Tryptophan 
C 
CUU (Leu/L) Leucine 
CUC (Leu/L) Leucine 
CCU (Pro/P) Proline 
CCC (Pro/P) Proline 
CAU (His/H) Histidine 
CAC (His/H) Histidine 
CGU (Arg/R) Arginine 
CGC (Arg/R) Arginine 
CUA (Leu/L) Leucine 
CUG (Leu/L) Leucine 
CCA (Pro/P) Proline 
CCG (Pro/P) Proline 
CAA (Gln/Q) Glutamine  
CAG (Gln/Q) Glutamine 
CGA (Arg/R) Arginine 
CGG (Arg/R) Arginine 
A 
AUU (Ile/I) Isoleucine 
AUC (Ile/I) Isoleucine 
ACU (Thr/T)Threonine 
ACC (Thr/T)Threonine 
AAU (Asn/N) Asparagine 
AAC (Asn/N) Asparagine 
AGU (Ser/S) Serine 
AGC (Ser/S) Serine 
AUA (Ile/I) Isoleucine ACA (Thr/T)Threonine AAA (Lys/K) Lysine AGA (Arg/R) Arginine 
AUG* (Met/M) Methionine ACG (Thr/T)Threonine AAG (Lys/K) Lysine AGG (Arg/R) Arginine 
G 
GUU (Val/V) Valine 
GUC (Val/V) Valine 
GCU (Ala/A) Alanine 
GCC (Ala/A) Alanine 
GAU (Asp/D) Aspartic acid 
GAC (Asp/D) Aspartic acid 
GGU (Gly/G) Glycine 
GGC (Gly/G) Glycine 
GUA (Val/V) Valine 
GUG (Val/V) Valine 
GCA (Ala/A) Alanine 
GCG (Ala/A) Alanine 
GAA (Glu/E) Glutamic acid 
GAG (Glu/E) Glutamic acid 
GGA (Gly/G) Glycine 
GGG (Gly/G) Glycine 
*
 The codon AUG both codes for methionine and serves as an initiation site: the first AUG in an mRNA's 
coding region is where translation into protein begins (Shine and Dalgarno 1974, Nakamoto 2009).          
 
 























Inverse RNA codon table with One- and Three-letter-code of the amino acids. 
 
 
Inverse codon table  
Ala/A GCU, GCC, GCA, GCG Leu/L UUA, UUG, CUU, CUC, CUA, CUG 
Arg/R CGU, CGC, CGA, CGG, AGA, 
AGG 
Lys/K AAA, AAG 
Asn/N AAU, AAC Met/M AUG 
Asp/D GAU, GAC Phe/F UUU, UUC 
Cys/C UGU, UGC Pro/P CCU, CCC, CCA, CCG 
Gln/Q CAA, CAG Ser/S UCU, UCC, UCA, UCG, AGU, AGC 
Glu/E GAA, GAG Thr/T ACU, ACC, ACA, ACG 
Gly/G GGU, GGC, GGA, GGG Trp/W UGG 
His/H CAU, CAC Tyr/Y UAU, UAC 
Ile/I AUU, AUC, AUA Val/V GUU, GUC, GUA, GUG 
START AUG STOP UAA, UGA, UAG 
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